WO2019040919A1 - OCULAR PHARMACEUTICAL COMPOSITIONS - Google Patents

OCULAR PHARMACEUTICAL COMPOSITIONS Download PDF

Info

Publication number
WO2019040919A1
WO2019040919A1 PCT/US2018/048025 US2018048025W WO2019040919A1 WO 2019040919 A1 WO2019040919 A1 WO 2019040919A1 US 2018048025 W US2018048025 W US 2018048025W WO 2019040919 A1 WO2019040919 A1 WO 2019040919A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
active agent
formula
pharmaceutically acceptable
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/048025
Other languages
English (en)
French (fr)
Inventor
Alan Verkman
Marc H. LEVIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2018321926A priority Critical patent/AU2018321926B2/en
Priority to CA3073718A priority patent/CA3073718A1/en
Priority to KR1020207008360A priority patent/KR20200044873A/ko
Priority to JP2020511176A priority patent/JP2020531511A/ja
Priority to US16/641,621 priority patent/US11839616B2/en
Priority to EP18849250.8A priority patent/EP3672598A4/en
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to CN201880069116.7A priority patent/CN111629730A/zh
Priority to RU2020111560A priority patent/RU2818087C2/ru
Publication of WO2019040919A1 publication Critical patent/WO2019040919A1/en
Anticipated expiration legal-status Critical
Priority to US18/497,962 priority patent/US20240156828A1/en
Priority to US19/296,874 priority patent/US20250367207A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • Dry eye disorders constitute a significant health care burden, particularly in an aging population.
  • Current treatment options include artificial tears, punctal plugs, and the topical antiinflammatory drugs cyclosporine and lifitegrast. References 1-3.
  • pro-secretory therapy in dry eye as increasing the volume of tear fluid bathing the ocular surface is predicted to reduce tear fluid hyperosmolality, which drives the downstream inflammatory response and consequent symptoms. Described herein, inter alia, are solutions to these and other problems in the art.
  • the disclosure provides methods of increasing tear production in an eye of a patient in need thereof by topically administering to the eye of the patient a pharmaceutical composition comprising about 5 micrograms or more of an active agent to increase tear production; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the disclosure provides methods of treating a dry eye disease in a patient in need thereof by topically administering to an eye of the patient a pharmaceutical composition comprising about 5 micrograms or more of an active agent to treat the dry eye disease; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the disclosure provides methods of increasing tear production in an eye of a patient in need thereof by topically administering to the eye of the patient a pharmaceutical composition comprising about 2 nanomoles or more of an active agent to increase tear production; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the disclosure provides methods of treating a dry eye disease in a patient in need thereof, the method comprising topically administering to an eye of the patient a pharmaceutical composition comprising about 2 nanomoles or more of an active agent to treat the dry eye disease; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the disclosure provides methods of increasing tear production in an eye of a patient in need thereof by topically administering to the eye of the patient a pharmaceutical composition comprising a therapeutically effective amount of an active agent to increase tear production; wherein the therapeutically effective amount provides a concentration of the an active agent in an amount of about 500 nM or more in the tear fluid of the eye about 1 hour to about 12 hours after
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B,
  • the disclosure provides methods of treating a dry eye disease in a patient in need thereof by topically administering to an eye of the patient a pharmaceutical composition comprising a therapeutically effective amount of an active agent to treat the dry eye disease; wherein the therapeutically effective amount provides a concentration of the active agent in an amount of (i) about 500 nM or more in the tear fluid of the eye about 30 minutes to about 3 hours after administration, or (ii) about 10 nM or more in the tear fluid of the eye about 4 hours to about to about 12 hours after administration; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the disclosure provides methods of increasing tear production in an eye of a patient in need thereof by topically administering once per day or twice per day to the eye of the patient a pharmaceutical composition comprising an active agent to increase tear production; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the disclosure provides methods of treating a dry eye disease in a patient in need thereof by topically administering once per day or twice per day to an eye of the patient a pharmaceutical composition comprising an active agent to treat the dry eye disease; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • compositions comprising about 5 micrograms or more of an active agent and a pharmaceutically acceptable carrier; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • compositions comprising an active agent and a pharmaceutically acceptable carrier; wherein the composition comprises the active agent at a concentration from about 1 nanomole to about 25 nmoles per 0.5 mL; and wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the disclosure provides eye droppers for delivering a drop of a topical pharmaceutical composition to the eye of a patient; wherein the eye dropper comprises any of the topical pharmaceutical compositions described herein.
  • the disclosure provides kits comprising the eye droppers described herein.
  • kits comprising an eye dropper, a container which comprises any of the topical pharmaceutical compositions described herein, and instructions for use.
  • the disclosure provides methods of identifying a patient for treatment with a modulator of ocular surface membrane transport or a modulator of intracellular signaling by (i) measuring the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, at an ocular surface of the patient; (ii) comparing the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, to a control; and (iii) identifying that the patient should be treated with the modulator of ocular surface membrane transport or a modulator of intracellular signaling if the change in the open-circuit transepithelial potential difference is lower than that of the control.
  • CFTRa C t-K267 is also referred to in the disclosure as Compound A.
  • FIGS. 1 A-B provide a schematic (FIG. 1 A) and photograph (FIG. IB) of an ocular surface potential difference (PD) recording method.
  • the perfusion catheter coupled to the measuring electrode was oriented perpendicular to the ocular surface near the medial canthus.
  • the eyelids created a natural reservoir for corneal and conjunctival exposure, with vacuum aspiration maintaining a stable perfusate volume.
  • FIGS. 2A-D show an the electrophysiological analysis of CFTR activation by CFTRact- K267 at the rabbit ocular surface.
  • FIG. 2A is a representative ocular surface PD recording in response to sequential solution exchanges.
  • FIG. 2C is a representative short- circuit current (Isc) measurement in freshly isolated rabbit forniceal and palpebral conjunctiva in response to compound additions.
  • FIGS. 3A-C show that CFTRa C t-K267 increases tear fluid at the rabbit ocular surface as measured by Schirmer's test.
  • FIG. 3A shows the tear volume (mm, by Schirmer's test) measured just before and at the indicated times after single-dose topical application of 3 nmol of CFTRact- K267 or formulation (containing 0.3% CMC) control (mean ⁇ S.E.M., 8 eyes per condition).
  • FIG. 3B shows the dose-dependence with study done as in FIG. 3 A, comparing 0.75, 1.5 and 6.0 nmol CFTRact-K267 (4 eyes per condition).
  • FIG. 3C shows the effect of formulation viscosity, with study done as in FIG. 3 A, for formulation containing 0.665%) CMC instead of 0.3%> CMC (4 eyes per condition).
  • FIGS. 4A-B shows the CFTR act -K267 concentration in rabbit tear fluid following instillation of a single 3-nmol dose.
  • FIG. 4A is a standard LC/MS curve of aqueous solutions containing specified concentrations of Compound A.
  • FIG. 4B shows the recovered CFTR ac t-K267 (in picomoles, closed circles, left ordinate) and deduced concentration (in nM, open circles, right ordinate) in tear fluid. Each point is the average of measurements done on 2 eyes for each time point.
  • FIGS. 5A-5C show ocular toxicity studies in a chronic CFTR ac t-K267 administration model. Rabbits were treated with 3 nmol CFTRact-K267 (or vehicle control) twice daily for 28 days. STT (FIG. 5A), IOP (FIG. 5B) and central corneal thickness (FIG. 5C) is graphed before and weekly following initiation of CFTR ac t-K267 administration (mean ⁇ S.E.M., 8 eyes). ** P ⁇ 0.01, ANOVA, comparing CFTRa C t-K267 vs. vehicle-treated.
  • FIGS 6A-C show representative photographs taken before and at day 28.
  • FIG. 6B shows lissamine green staining scores (mean ⁇ S.E.M., 8 eyes).
  • FIG. 6C shows H&E staining of cornea and conjunctiva at day 28. Representative of sections done on 2 eyes per group. S, stroma; CD, corneal endothelium. Scale bars: 100 ⁇ (cornea), 25 ⁇ (conjunctiva).
  • FIGS. 7A-B show tissue levels following chronic CFTR ac t-K267 administration (3 nmol twice-daily for 28 days).
  • FIG. 7A is a representative LC/MS elution curves shown for CFTRact- K267 in indicated tissues.
  • FIG. 7B shows CFTR ac t-K267 levels in ocular and extraocular tissues (mean ⁇ S.E.M., 8 rabbits).
  • LC/MS detection limit shown as vertical dashed line.
  • active agent refers to a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof.
  • active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof.
  • active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.
  • active agent is Compound A or a pharmaceutically acceptable salt thereof.
  • active agent is Compound B or a pharmaceutically acceptable salt thereof.
  • active agent is Compound C or a pharmaceutically acceptable salt thereof.
  • active agent is Compound D or a pharmaceutically acceptable salt thereof.
  • active agent is Compound E or a pharmaceutically acceptable salt thereof.
  • 5 micrograms of a pharmaceutically acceptable salt of Compound A means that there is 5 micrograms of the free base form of Compound A.
  • the terms “nanomoles” or “nM” or “nmoles” when referencing the unit of measurement of an active agent refers to nanomoles of the free base form of the active agent regardless of whether the active agent is present in the form of the free base or the pharmaceutically acceptable salt.
  • 5 nanomoles of a pharmaceutically acceptable salt of Compound A means that there is 5 nanomoles of the free base form of Compound A.
  • “Tear fluid” or “tears” or “tear” refer to the watery fluid secreted by the lacrimal glands between the surface of the eye and the eyelid that serve to moisten, lubricate, and protect the eye.
  • Increasing tear production refers to increasing the tear production in a patient relative to a control.
  • the control can be the same patient prior to treatment, a statistical group of patients who have not been treated, or a different patient who has not been treated.
  • increasing tear production refers to doubling the tear production of the patient when compared to the tear production of the patient prior to treatment (or when compared to another control) with the active agents described herein.
  • increasing tear production refers to tripling or
  • increasing tear production refers to increasing the tear production of a patient to within a normal range of tear production for the patient relative to a control or to applicable standards known in the art.
  • Methods of measuring tear production are known in the art, and include, for example,
  • increasing tear production refers to an increase in tear production to at least 5 mm of moisture on a filter paper after about 5 minutes following Schirmer's tear test II.
  • increasing tear production refers to an increase in tear production from about 5 mm to about 10 mm of moisture on a filter paper after about 5 minutes following Schirmer's tear test II.
  • increasing tear production refers to increasing the results of the Schirmer's tear tests relative to the results prior to administration of the active agents and compositions described herein.
  • Dry eye disease is a disease in which a patient experiences dryness in one or both eyes. Dry eye disease is marked by an insufficient quality or quantity of tear production. Exemplary symptoms of dry eye disease include irritation, burning, stinging, discharge, foreign body sensation, tearing, blurred vision, or a combination of two or more symptoms. Dry eye disease may alternatively be referred to as dry eye syndrome, keratoconjunctivitis sicca, dysfunctional tear syndrome, or lacrimal keratoconjunctivitis. Dry eye disease may be caused by medications, advanced age, rosacea, blepharitis, autoimmune disorders (e.g., Sjogren's syndrome), diabetes, thyroid disorders, Vitamin A deficiency, environmental conditions (e.g., dry or windy
  • dry eye disease may be diagnosed by Schirmer's tear tests and/or ocular surface staining patterns of
  • Lissamine green, Rose Bengal, and/or fluorescein dyes Lissamine green, Rose Bengal, and/or fluorescein dyes.
  • Patient and “patient in need thereof refer to a living organism suffering from or prone to a disease that can be treated by administration of the active agents described herein.
  • Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, and other non-mammalian animals.
  • the patient is human.
  • the patient is a dog.
  • the patient is a cat.
  • treating refers to any indicia of success in the treatment or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; or improving a patient's physical well-being.
  • the treatment of symptoms can be based on objective or subjective parameters, including the results of a physical examination.
  • treating includes prevention of an injury, pathology, condition, or disease.
  • Treating in reference to a treating a symptom of a dry eye disease refers to: (i) reducing the severity of one or more symptoms; (ii) eliminating one or more symptoms; (iii) reducing the duration of one or more symptoms; (iv) preventing the recurrence or onset of one or more symptoms; or (iv) a combination of two or more thereof.
  • a “therapeutically effective amount” is an amount of the active agent sufficient to accomplish a stated purpose, e.g., achieve the effect for which it is administered (i.e., increasing tear production), treat a dry eye disease, or reduce one or more symptoms of dry eye disease in a patient.
  • a “therapeutically effective amount” is an amount of the active agent sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage
  • the "therapeutically effective amount” is the amount described herein.
  • Dosages of the active agent may be varied depending upon the requirements of the patient and the active agent being employed.
  • the dose administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time.
  • the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment can optionally be initiated with smaller dosages which are less than the optimum dose of the active agent. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. Dosage amounts and intervals can be adjusted individually to provide levels of the administered active agent effective for the particular clinical indication being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state. Appropriate dosages for increasing tear production and treating dry eye disease are described in detail herein.
  • the dosage and frequency (once/daily, twice/daily) of the active agent administered to a patient can vary depending upon a variety of factors, for example, whether the patient suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the patient; nature and extent of symptoms of the disease being treated, kind of concurrent treatment, complications from the disease being treated or other health-related problems.
  • Other therapeutic regimens or agents can be used in conjunction with the methods and active agents described herein. Adjustment and manipulation of established dosages (e.g., frequency and duration) are well within the ability of those skilled in the art.
  • the active agents and compositions may be administered once or twice per day.
  • the active agents and compositions described herein may be administered once per day for about two weeks. In embodiments, the active agents and compositions described herein may be administered once per day for about one month. In embodiments, the active agents and compositions described herein may be administered twice per day for about two weeks. In embodiments, the active agents and compositions described herein may be administered twice per day for about one month.
  • a "week” is from about 13 days to about 15 days. In embodiments, a week is 14 days.
  • a 'month" is 28 days, 29 days, 30, days, or 31 days. In embodiments, a month is 28 days. In embodiments, a month is 30 days. In embodiments, a month is 31 days.
  • the active agents and compositions described herein can be used in combination with one or more other drugs known to be useful in treating dry eye disease or increasing tear production.
  • the active agents and compositions described herein can be used with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
  • the active agents described herein may be co-administered with one or more other drugs that are useful to treat dry eye disorder or increase tear production in patients.
  • Exemplary drugs used to treat dry eye disorder or to increase tear production include epithelial sodium channel inhibitors, lymphocyte function- associated antigen- 1 antagonists, anti-inflammatory agents, cholinergic agonists, steroids, antibiotics, and the like.
  • An exemplary epithelial sodium channel inhibitor is amiloride.
  • An exemplary lymphocyte function-associated antigen- 1 antagonist is lifitegrast.
  • An exemplary anti- inflammatory agent is cyclosporine.
  • Exemplary cholinergic agonists are pilocarpine and cevimeline.
  • An exemplary steroid is a corticosteroid.
  • co-administer it is meant that active agent or compositions described herein are administered at the same time, prior to (e.g., minutes or hours), or after (e.g., minutes or hours) the administration of one or more additional therapies.
  • the active agents described herein can be administered alone or can be co-administered to the patient.
  • Co-administration is meant to include simultaneous or sequential administration of the active agent individually or in combination.
  • the preparations can also be combined, when desired, with other active substances.
  • Co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second pharmaceutical compound (e.g. anti-dry eye agents). Also contemplated herein, are embodiments, where co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a another pharmaceutical compound. Co-administration includes administering the active agent and other pharmaceutical compound simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. Co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both the active agent and the other pharmaceutical compound. In other embodiments, the active agent and other pharmaceutical compound can be formulated separately.
  • Control or "control experiment” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects.
  • modulator refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule.
  • modulate is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties. “Modulation” refers to the process of changing or varying one or more properties. For example, a modulator of a target protein changes by increasing or decreasing a property or function of the target molecule or the amount of the target molecule. A modulator of a disease decreases a symptom, cause, or characteristic of the targeted disease.
  • “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a patient and can be included in the compositions described herein.
  • Exemplary pharmaceutically acceptable excipients include stabilizers, co-solvents, and the like.
  • Other non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like.
  • Such preparations can be sterilized and, if desired, mixed with other pharmaceutically acceptable excipients such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like.
  • excipients such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like.
  • a “stabilizer” refers to a pharmaceutically acceptable excipient that maintains the properties of the active agents described herein and/or that delays or prevents physical or chemical degradation of the active agents described herein.
  • Exemplary stabilizers include microcrystalline cellulose, carboxymethyl cellulose, hydromellose, dextran, and the like.
  • “Co-solvent” refers to pharmaceutically acceptable excipients that can increase, maintain, or prolong the solubility of the active agents.
  • Exemplary co-solvents include sorbitol, glycerol, propylene glycol, polyethylene glycol, polyvinyl alcohol, polysorbate, and the like.
  • administering means topical administration of the active agents and compositions described herein to one or both eyes of a patient.
  • the topical administration is topical administration to the conjunctiva of the eye.
  • the topical administration is topical administration to the conjunctival sac of the eye.
  • the topical administration is topical administration to the conjunctiva of the eye and the conjunctival sac of the eye.
  • the active agents and compositions described herein can be delivered topically as a liquid formulation.
  • the topical liquid formulation is a solution.
  • the topical liquid formulation is an aqueous solution. In embodiments, the topical liquid formulation is a suspension. In embodiments, the topical liquid formulation is an
  • Solution has the plain and ordinary meaning as used in the chemical and biological arts, and refers to a formulation in which an active agent is dissolved in a suitable solvent (e.g., aqueous solvent, organic solvent).
  • a suitable solvent e.g., aqueous solvent, organic solvent.
  • Supension has the plain and ordinary meaning as used in the chemical and biological arts, and refers to a formulation in which an insoluble active agent is dispersed in a suitable solvent (e.g., aqueous solvent, organic solvent).
  • Emmulsion has the plain and ordinary meaning as used in the chemical and biological arts, and refers to two or more immiscible liquids in which one liquid is uniformly dispersed throughout the other liquid.
  • the active agent may be present in one or both immiscible liquids
  • Micronized refers to the active agent having a particle size distribution D90 of about 25 microns or less or to a particle size range from about 1 micron to about 25 microns. In embodiments, micronized particles of the active agent have a particle size distribution D90 of about 20 microns or less, or about 15 microns or less, or about 10 microns or less. In
  • micronized particles of the active agent have a particle size range from about 1 micron to about 20 microns, or about 2 microns to about 15 microns, or about 2 microns to about 10 microns.
  • Methods of micronizing pharmaceutical compounds are conventional and well known in the art of pharmaceutical chemistry. Methods of Treatment
  • the disclosure provides methods of increasing tear production in an eye of a patient in need thereof by topically administering once per day or twice per day to the eye of the patient a pharmaceutical composition comprising an active agent to increase tear production; wherein the active agent comprises a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C,
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is a compound of Formula (II) or a
  • the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound A or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound B or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound C or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound D or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound E or a pharmaceutically acceptable salt thereof. In embodiments, the pharmaceutical composition is a liquid pharmaceutical composition. In embodiments, the liquid pharmaceutical composition is a solution, a suspension, or an emulsion. In embodiments, the liquid pharmaceutical composition is an aqueous solution. In embodiments, the liquid pharmaceutical composition is a suspension; and the active agent is micronized. In
  • the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipient is a stabilizer, a co- solvent, or a combination thereof.
  • the methods comprise topically
  • the methods comprise topically administering the pharmaceutical composition to the conjunctival sac of the eye.
  • the pharmaceutical composition is administered once per day. In embodiments, the pharmaceutical composition is administered twice per day.
  • the composition is administered for about 14 days. In embodiments, the composition is administered for about one month.
  • the methods further comprise administering an epithelial sodium channel inhibitor, a lymphocyte function-associated antigen-1 antagonist, an anti-inflammatory agent, a cholinergic agonist, a steroid, an antibiotic, or a combination of two or more thereof.
  • the epithelial sodium channel inhibitor is amiloride; wherein the lymphocyte function-associated antigen-1 antagonist is lifitegrast; wherein the anti-inflammatory agent is cyclosporine; wherein the cholinergic agonist is pilocarpine or cevimeline; and wherein the steroid is a corticosteroid.
  • the patient is a human.
  • the patient has an open-circuit transepithelial potential difference on the eye that is lower than that of a control.
  • the methods further comprise measuring the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, at the surface of the eye of the patient, and comparing the result to a control.
  • the disclosure provides methods of treating a dry eye disease in a patient in need thereof by topically administering once per day or twice per day to an eye of the patient a pharmaceutical composition comprising an active agent to treat the dry eye disease; wherein the active agent comprises a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C,
  • the disclosure provides methods of treating a symptom of dry eye disease in a patient in need thereof by topically administering once per day or twice per day to an eye of the patient a pharmaceutical composition comprising an active agent to treat the symptom of the dry eye disease; wherein the active agent comprises a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A,
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound A or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound B or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound C or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound D or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound E or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is a liquid pharmaceutical composition. In embodiments, the liquid pharmaceutical composition is a solution, a suspension, or an emulsion. In embodiments, the liquid pharmaceutical composition is an aqueous solution. In embodiments, the liquid pharmaceutical composition is a suspension; and active agent is micronized. In embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. In embodiments, the pharmaceutically acceptable excipient is a stabilizer, a co- solvent, or a combination thereof. In embodiments, the methods comprise topically
  • the methods comprise topically administering the pharmaceutical composition to the conjunctival sac of the eye.
  • the pharmaceutical composition is administered once per day. In embodiments, the pharmaceutical composition is administered twice per day.
  • the composition is administered for about 14 days. In embodiments, the composition is administered for about one month.
  • the methods further comprise administering a epithelial sodium channel inhibitor, a lymphocyte function-associated antigen-1 antagonist, an anti-inflammatory agent, a cholinergic agonist, a steroid, an antibiotic, or a combination of two or more thereof.
  • the epithelial sodium channel inhibitor is amiloride; wherein the lymphocyte function-associated antigen- 1 antagonist is lifitegrast; wherein the anti-inflammatory agent is cyclosporine; wherein the cholinergic agonist is pilocarpine or cevimeline; and wherein the steroid is a corticosteroid.
  • the patient is a human.
  • the patient has open-circuit transepithelial potential difference on the eye that is lower than that of a control.
  • the methods further comprise measuring the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, at the surface of the eye of the patient, and comparing the result to a control.
  • the disclosure provides methods of increasing tear production in an eye of a patient in need thereof by topically administering to the eye of the patient a pharmaceutical composition comprising a therapeutically effective amount of an active agent to increase tear production; wherein the active agent comprises a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B,
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound A or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound B or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound C or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound D or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound E or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is a liquid pharmaceutical composition. In embodiments, the liquid pharmaceutical composition is a solution, a suspension, or an emulsion. In embodiments, the liquid pharmaceutical composition is an aqueous solution. In embodiments, the liquid pharmaceutical composition is a suspension; the active agent is micronized. In embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. In embodiments, the pharmaceutically acceptable excipient is a stabilizer, a co-solvent, or a combination thereof. In embodiments, the methods comprise topically administering the pharmaceutical composition to the conjunctiva of the eye.
  • the methods comprise topically administering the pharmaceutical composition to the conjunctival sac of the eye.
  • the pharmaceutical composition is administered once per day.
  • the pharmaceutical composition is administered twice per day.
  • the composition is administered for about 14 days.
  • the composition is administered for about one month.
  • the methods further comprise administering a epithelial sodium channel inhibitor, a lymphocyte function-associated antigen-1 antagonist, an anti-inflammatory agent, a cholinergic agonist, a steroid, an antibiotic, or a combination of two or more thereof.
  • the epithelial sodium channel inhibitor is amiloride; wherein the lymphocyte function-associated antigen-1 antagonist is lifitegrast; wherein the antiinflammatory agent is cyclosporine; wherein the cholinergic agonist is pilocarpine or cevimeline; and wherein the steroid is a corticosteroid.
  • the patient is a human.
  • the patient has an open-circuit transepithelial potential difference on the eye that is lower than that of a control.
  • the methods further comprise measuring the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, at the surface of the eye of the patient, and comparing the result to a control.
  • the pharmaceutical composition comprises a therapeutically effective amount of an active agent; wherein the therapeutically effective amount of the active agent is about 1 microgram or more. In embodiments, the therapeutically effective amount of the active agent is from about 1 microgram to about 100 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 100 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 75 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 50 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 35 micrograms. In
  • the therapeutically effective amount of the active agent is from about 5
  • the therapeutically effective amount of the active agent is from about 5 micrograms to about 15 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 8 micrograms to about 12 micrograms. In embodiments, the therapeutically effective amount of the active agent is about 10 micrograms. In embodiments, the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the pharmaceutical composition comprises a therapeutically effective amount of the active agent; wherein the therapeutically effective amount is about 2 nanomoles or more.
  • the therapeutically effective amount of the active agent is from about 2 nanomoles to about 100 nanomoles.
  • the therapeutically effective amount of the active agent is from about 2 nanomoles to about 75 nanomoles.
  • the therapeutically effective amount of the active agent is from about 2 nanomoles to about 50 nanomoles.
  • the therapeutically effective amount of the active agent is from about 2 nanomoles to about 25 nanomoles.
  • the therapeutically effective amount of the active agent is from about 2 nanomoles to about 15 nanomoles. In embodiments, the therapeutically effective amount of the active agent is from about 2 nanomoles to about 10 nanomoles. In embodiments, the therapeutically effective amount of the active agent is from about 2 nanomoles to about 5 nanomoles. In embodiments, the therapeutically effective amount of the active agent is about 3 nanomoles. In embodiments, the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A,
  • the disclosure provides methods of treating a dry eye disease in a patient in need thereof by topically administering to an eye of the patient a pharmaceutical composition comprising a therapeutically effective amount of an active agent to treat the dry eye disease; wherein the active agent comprises a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B,
  • the disclosure provides methods of treating a symptom of dry eye disease in a patient in need thereof by topically administering to an eye of the patient a pharmaceutical composition comprising a therapeutically effective amount of an active agent to treat the symptom of the dry eye disease; wherein the active agent comprises a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is a compound of Formula (IV) or a
  • the active agent is Compound A or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound B or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound C or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound D or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound E or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is a liquid pharmaceutical composition.
  • the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • the liquid pharmaceutical composition is an aqueous solution.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipient is a stabilizer, a co-solvent, or a combination thereof.
  • the methods comprise topically administering the pharmaceutical composition to the conjunctiva of the eye. In embodiments, the methods comprise topically administering the pharmaceutical composition to the conjunctival sac of the eye. In embodiments, the pharmaceutical composition is administered once per day. In embodiments, the pharmaceutical composition is administered twice per day. In embodiments, the composition is administered for about 14 days. In embodiments, the composition is administered for about one month.
  • the methods further comprise administering a epithelial sodium channel inhibitor, a lymphocyte function-associated antigen-1 antagonist, an anti-inflammatory agent, a cholinergic agonist, a steroid, an antibiotic, or a combination of two or more thereof.
  • the epithelial sodium channel inhibitor is amiloride; wherein the lymphocyte function-associated antigen-1 antagonist is lifitegrast; wherein the anti-inflammatory agent is cyclosporine; wherein the cholinergic agonist is pilocarpine or cevimeline; and wherein the steroid is a corticosteroid.
  • the patient is a human.
  • the patient has an open-circuit transepithelial potential difference on the eye that is lower than that of a control.
  • the methods further comprise measuring the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, at the surface of the eye of the patient, and comparing the result to a control.
  • the pharmaceutical composition comprises a therapeutically effective amount of the active agent; wherein the therapeutically effective amount is about 1 microgram or more. In embodiments of the methods of treating a symptom of dry eye disease described herein, the pharmaceutical composition comprises a therapeutically effective amount of the active agent; wherein the therapeutically effective amount is about 1 microgram or more. In embodiments, the therapeutically effective amount of the active agent is about 5 micrograms or more. In embodiments, the therapeutically effective amount of the active agent is from about 1 microgram to about 100 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 100 micrograms.
  • the therapeutically effective amount of the active agent is from about 5 micrograms to about 75 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 50 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 35 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 20 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 15 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 8 micrograms to about 12 micrograms. In
  • the therapeutically effective amount of the active agent is about 10 micrograms.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B,
  • the pharmaceutical composition comprises a therapeutically effective amount of the active agent; wherein the therapeutically effective amount of the active agent is about 2 nanomoles or more.
  • the pharmaceutical composition comprises a therapeutically effective amount of the active agent; wherein the therapeutically effective amount of the active agent is about 2 nanomoles or more.
  • the therapeutically effective amount of the active agent is from about 2 nanomoles to about 100 nanomoles.
  • the therapeutically effective amount of the active agent is from about 2 nanomoles to about 75 nanomoles.
  • the pharmaceutical composition comprises a therapeutically effective amount of the active agent; wherein the therapeutically effective amount of the active agent is about 2 nanomoles or more.
  • therapeutically effective amount of the active agent is from about 2 nanomoles to about 50 nanomoles. In embodiments, the therapeutically effective amount of the active agent is from about 2 nanomoles to about 25 nanomoles. In embodiments, the therapeutically effective amount of the active agent is from about 2 nanomoles to about 15 nanomoles. In embodiments, the therapeutically effective amount of the active agent is from about 2 nanomoles to about 10 nanomoles. In embodiments, the therapeutically effective amount of the active agent is from about 2 nanomoles to about 5 nanomoles. In embodiments, the therapeutically effective amount of the active agent is about 3 nanomoles.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a
  • the disclosure provides methods of increasing tear production in an eye of a patient in need thereof by topically administering to the eye of the patient a pharmaceutical composition comprising a therapeutically effective amount of an active agent to increase tear production; wherein the therapeutically effective amount provides a concentration of the of the active agent in an amount of about 500 nM or more in the tear fluid of the eye about 1 hour to about 12 hours after administration; and wherein the active agent comprises a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV),
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound A or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound B or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound C or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound D or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound E or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is a liquid pharmaceutical composition. In embodiments, the liquid pharmaceutical composition is a solution, a suspension, or an emulsion. In embodiments, the liquid pharmaceutical composition is an aqueous solution. In embodiments, the liquid pharmaceutical composition is a suspension; and the active agent is micronized. In embodiments, the pharmaceutical composition further comprises a
  • the methods comprise topically administering the pharmaceutical composition to the conjunctiva of the eye. In embodiments, the methods comprise topically administering the pharmaceutical composition to the conjunctival sac of the eye. In embodiments, the pharmaceutical composition is administered once per day. In embodiments, the pharmaceutical composition is administered twice per day. In embodiments, the composition is administered for about 14 days. In embodiments, the composition is administered for about one month.
  • the methods further comprise administering a epithelial sodium channel inhibitor, a lymphocyte function-associated antigen-1 antagonist, an anti-inflammatory agent, a cholinergic agonist, a steroid, an antibiotic, or a combination of two or more thereof.
  • the epithelial sodium channel inhibitor is amiloride; wherein the lymphocyte function-associated antigen-1 antagonist is lifitegrast; wherein the anti-inflammatory agent is cyclosporine; wherein the cholinergic agonist is pilocarpine or cevimeline; and wherein the steroid is a corticosteroid.
  • the patient is a human.
  • the patient has an open-circuit transepithelial potential difference on the eye that is lower than that of a control.
  • the methods further comprise measuring the change in the open-circuit
  • transepithelial potential difference in response to contact with different solutions, at the surface of the eye of the patient, and comparing the result to a control.
  • the therapeutically effective amount provides a concentration of the active agent in an amount of about 500 nM or more in the tear fluid of the eye about 1 hour to about 12 hours after administration. In embodiments, the therapeutically effective amount provides a concentration of the active agent in an amount of (i) about 500 nM or more in the tear fluid of the eye about 30 minutes to about 3 hours after administration, or (ii) about 10 nM or more in the tear fluid of the eye about 4 hours to about to about 12 hours after administration, or (iii) both (i) and (ii).
  • the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 500 nM to about 5,000 nM about 1 hour to about 3 hours after administration, or (ii) about 10 nM to about 2,000 nM about 4 hours to about 8 hours after administration, or (iii) both (i) and (ii). In embodiments, the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 500 nM to about 2,000 nM about 1 hour to about 3 hours after administration, or (ii) about 25 nM to about 1,000 nM about 4 hours to about 8 hours after administration, or (iii) both (i) and (ii).
  • the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 500 nM to about 1,500 nM about 1 hour to about 3 hours after administration, or (ii) about 50 nM to about 500 nM about 5 hours to about 7 hours after administration, or (iii) both (i) and (ii). In embodiments, the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 750 nM to about 1,250 nM about 1 hour to about 3 hours after administration, or (ii) about 50 nM to about 200 nM about 5 hours to about 7 hours after administration, or (iii) both (i) and (ii).
  • the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 1000 nM about 2 hours after administration, or (ii) about 100 nM about 6 hours after administration, or (iii) both (i) and (ii).
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the disclosure provides methods of treating a dry eye disease in a patient in need thereof by topically administering to an eye of the patient a pharmaceutical composition comprising a therapeutically effective amount of an active agent to treat the dry eye disease; wherein the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 500 nM or more in the tear fluid of the eye about 30 minutes to about 12 hours after administration; wherein the active agent comprises a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV),
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound A or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound B or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound C or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound D or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound E or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is a liquid pharmaceutical composition. In embodiments, the liquid pharmaceutical composition is a solution, a suspension, or an emulsion. In embodiments, the liquid pharmaceutical composition is an aqueous solution. In embodiments, the liquid pharmaceutical composition is a suspension; and the active agent is micronized. In embodiments, the pharmaceutical composition further comprises a
  • the methods comprise topically administering the pharmaceutical composition to the conjunctiva of the eye. In embodiments, the methods comprise topically administering the pharmaceutical composition to the conjunctival sac of the eye. In embodiments, the pharmaceutical composition is administered once per day. In embodiments, the pharmaceutical composition is administered twice per day. In embodiments, the composition is administered for about 14 days. In embodiments, the composition is administered for about one month.
  • the methods further comprise administering an epithelial sodium channel inhibitor, a lymphocyte function-associated antigen-1 antagonist, an anti-inflammatory agent, a cholinergic agonist, a steroid, an antibiotic, or a combination of two or more thereof.
  • the epithelial sodium channel inhibitor is amiloride; wherein the lymphocyte function-associated antigen-1 antagonist is lifitegrast; wherein the anti-inflammatory agent is cyclosporine; wherein the cholinergic agonist is pilocarpine or cevimeline; and wherein the steroid is a corticosteroid.
  • the patient is a human.
  • the patient has an open-circuit transepithelial potential difference on the eye that is lower than that of a control.
  • the methods further comprise measuring the change in the open-circuit
  • transepithelial potential difference in response to contact with different solutions, at the surface of the eye of the patient, and comparing the result to a control.
  • the therapeutically effective amount provides a concentration of the active agent in an amount from in an amount of about 500 nM or more in the tear fluid of the eye about 1 hour to about 12 hours after administration. In embodiments, the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 500 nM or more in the tear fluid of the eye about 30 minutes to about 3 hours after administration, or (ii) about 10 nM or more in the tear fluid of the eye about 4 hours to about to about 12 hours after administration, or (iii) both (i) and (ii).
  • the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 500 nM to about 5,000 nM about 1 hour to about 3 hours after administration, or (ii) about 10 nM to about 2,000 nM about 4 hours to about 8 hours after administration, or (iii) both (i) and (ii). In embodiments, the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 500 nM to about 2,000 nM about 1 hour to about 3 hours after administration, or (ii) about 25 nM to about 1,000 nM about 4 hours to about 8 hours after administration, or (iii) both (i) and (ii).
  • the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 500 nM to about 1,500 nM about 1 hour to about 3 hours after administration, or (ii) about 50 nM to about 500 nM about 5 hours to about 7 hours after administration, or (iii) both (i) and (ii). In embodiments, the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 750 nM to about 1,250 nM about 1 hour to about 3 hours after administration, or (ii) about 50 nM to about 200 nM about 5 hours to about 7 hours after administration, or (iii) both (i) and (ii).
  • the therapeutically effective amount provides a concentration of the active agent in an amount from (i) about 1000 nM about 2 hours after administration, or (ii) about 100 nM about 6 hours after administration, or (iii) both (i) and (ii).
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • compositions a therapeutically effective amount of an active agent and a pharmaceutically acceptable carrier; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D,
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (III) or a
  • the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound A or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound B or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound C or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound D or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound E or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is a liquid pharmaceutical composition.
  • the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • the liquid pharmaceutical composition is a solution, a suspension, or an emulsion
  • the pharmaceutical composition is an aqueous solution.
  • the liquid pharmaceutical composition is a suspension; and the active agent is micronized.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipient is a stabilizer, a co-solvent, or a combination thereof.
  • the therapeutically effective amount of the active agent is about 1 microgram or more. In embodiments, the therapeutically effective amount of the active agent is about 5 micrograms or more. In embodiments, the therapeutically effective amount of the active agent is from about 1 microgram to about 100 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 100 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 75 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 50 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 35 micrograms. In
  • the therapeutically effective amount of the active agent is from about 5 micrograms to about 20 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 5 micrograms to about 15 micrograms. In embodiments, the therapeutically effective amount of the active agent is from about 8 micrograms to about 12 micrograms. In embodiments, the therapeutically effective amount of the active agent is about 10 micrograms. In embodiments, the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • compositions comprising an active agent and a pharmaceutically acceptable carrier; wherein the composition comprises the active agent at a concentration from about 1 nanomole to about 25 nmoles per 0.5 mL; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound A or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound B or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound C or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound D or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound E or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is a liquid pharmaceutical composition.
  • the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • the liquid pharmaceutical composition is an aqueous solution.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipient is a stabilizer, a co-solvent, or a combination thereof.
  • the topical pharmaceutical compositions described herein comprise the active agent at a concentration from about 1 nanomole to about 50 nmoles per 0.5 mL. In embodiments, the compositions comprise the active agent at a concentration from about 1 nanomole to about 25 nmoles per 0.5 mL. In embodiments, the compositions comprise the active agent at a concentration from about 1 nanomole to about 20 nmoles per 0.5 mL.
  • the compositions comprise the active agent at a concentration from about 1 nanomole to about 15 nmoles per 0.5 mL. In embodiments, the compositions comprise the active agent at a concentration from about 2 nanomoles to about 10 nmoles per 0.5 mL. In embodiments, the compositions comprise the active agent at a concentration from about 2 nanomoles to about 5 nmoles per 0.5 mL. In embodiments, the compositions comprise the active agent at a concentration from about 2 nanomoles to about 4 nmoles per 0.5 mL. In
  • the compositions comprise active agent at a concentration of about 3 nanomoles per 0.5 mL.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the disclosure provides eye droppers for delivering a drop of a topical pharmaceutical composition to the eye of a patient; wherein the eye dropper comprises a topical composition which comprises the active agent; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV),
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound A or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound B or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound C or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound D or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound E or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is a liquid pharmaceutical composition. In embodiments, the liquid pharmaceutical composition is a solution, a suspension, or an emulsion. In embodiments, the liquid pharmaceutical composition is an aqueous solution. In embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. In embodiments, the pharmaceutically acceptable excipient is a stabilizer, a co-solvent, or a combination thereof.
  • any eye dropper known in the art can be used to topically administer the compounds and compositions described herein.
  • the eye dropper has a volume sufficient to house from about 1 drop to about 50 drops of the pharmaceutical compositions described herein. In embodiments, the eye dropper has a volume sufficient to house from about 1 drop to about 25 drops of the pharmaceutical compositions described herein. In embodiments, the eye dropper has a volume sufficient to house from about 1 drop to about 20 drops of the pharmaceutical compositions described herein. In embodiments, the eye dropper has a volume sufficient to house from about 1 drop to about 15 drops of the pharmaceutical compositions described herein. In embodiments, the eye dropper has a volume sufficient to house from about 1 drop to about 10 drops of the pharmaceutical compositions described herein.
  • the eye dropper has a volume sufficient to house 1 to 5 drops of the composition. In embodiments, the eye dropper has a volume sufficient to house 1 to 4 drops of the composition. In embodiments, the eye dropper has a volume sufficient to house 1 to 3 drops of the composition. In embodiments, the eye dropper has a volume sufficient to house 1 or 2 drops of the composition.
  • a "drop” will be a volume of the pharmaceutical composition described herein that can provide a therapeutically effective amount of the compounds described herein when
  • a drop has a volume from about 10 ⁇ _, to about 100 ⁇ ⁇ . In embodiments, a drop has a volume from about 20 ⁇ _, to about 90 ⁇ ⁇ . In embodiments, a drop has a volume from about 30 ⁇ _, to about 80 ⁇ ..
  • a drop has a volume from about 40 ⁇ _, to about 70 ⁇ In embodiments, a drop has a volume from about 50 ⁇ _, to about 85 ⁇ In embodiments, a drop has a volume from about 30 ⁇ _, to about 65 ⁇ .. In embodiments, a drop has a volume from about 40 ⁇ _, to about 60 ⁇ .. In embodiments, a drop has a volume from about 55 ⁇ _, to about 65 ⁇
  • kits comprising the eye droppers described herein.
  • the kit can contain any number of eye droppers that can conveniently be used by the patient for
  • the kit will contain an amount of eye droppers to meet the frequency of the dosing regimen. In embodiments, the kit will contain one eye dropper that can be re-used for the duration of the treatment regimen. In embodiments, the kit will contain seven eye droppers, sufficient to provide single use eye droppers for one week of treatment. In embodiments, the kit will contain fourteen eye droppers. In
  • kits comprising an eye dropper, a container which comprises a topical pharmaceutical compositions which comprise the active agent, and instructions for use; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (II) or a
  • the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound A or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound B or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound C or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound D or a pharmaceutically acceptable salt thereof. In embodiments, the active agent is Compound E or a pharmaceutically acceptable salt thereof. In embodiments, the pharmaceutical composition is a liquid pharmaceutical composition. In embodiments, the liquid pharmaceutical composition is a solution, a suspension, or an emulsion. In embodiments, the liquid pharmaceutical composition is an aqueous solution. In embodiments, the liquid
  • composition is a suspension; and the active agent is micronized.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipient is a stabilizer, a co- solvent, or a combination thereof.
  • the kit can contain any number of eye droppers and any number of containers housing the pharmaceutical compositions that can conveniently be used by the patient for administration of the compositions described herein.
  • the kit will contain an amount of eye droppers and containers to meet the frequency of the dosing regimen.
  • the kit will comprise one eye dropper and one container; where the container comprises one dose of the composition.
  • the kit will comprise two eye droppers and one container;
  • the container comprises two doses of the composition.
  • the kit will comprise two eye droppers and two containers; wherein each container comprises one dose of the composition.
  • the kit will comprise seven eye droppers and seven
  • kits wherein each container comprises one dose of the composition.
  • the kit will comprise fourteen eye droppers and seven containers; wherein each container comprises two doses of the composition.
  • the kit will comprise fourteen eye droppers and fourteen containers; wherein each container comprises one dose of the composition.
  • the methods comprise the steps of: (i) measuring a change in an open-circuit transepithelial potential difference, in response to contact with different solutions, at an ocular surface of the patient; (ii) comparing the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, to a control; and (iii) identifying that the patient should be treated with the modulator of ocular surface membrane transport if the change in the open-circuit transepithelial potential difference is lower than that of the control.
  • the disclosure provides methods of identifying and treating a patient with a modulator of ocular surface membrane transport.
  • the methods comprise the steps of: (i) measuring a change in an open-circuit transepithelial potential difference, in response to contact with different solutions, at an ocular surface of the patient; (ii) comparing the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, to a control; (iii) identifying that the patient should be treated with the modulator of ocular surface membrane transport if the change in the open-circuit transepithelial potential difference is lower than that of the control; and (iv) treating the patient with a therapeutically effective amount of the modulator of ocular surface membrane transport.
  • the method involves perfusion of the ocular surface with a series of different solutions during continuous measurement of the potential difference using a high -impedance voltmeter. Solutions containing compounds that result in depolarizations or hyperpolarizations may be identified as modulators of ocular surface membrane transport. The lower the baseline magnitude of the measurement relative to a control may indicate the greater the ability of the compound to modulate ocular surface membrane transport, which identifies compounds that will be more efficacious in increasing tear production and treating dry eye disease. In embodiments, the modulators of ocular surface membrane transport activate or increase ocular surface membrane transport. In
  • the modulator of ocular surface membrane transport is a CFTR agonist, such as the compounds of Formula (I) described herein.
  • the ocular surface membrane transport is an ion transporter.
  • the ion transporter is a chloride transporter, a potassium transporter, or a bicarbonate transporter.
  • the ocular surface membrane transport is a biomolecule transporter.
  • the biomolecule transporter is a glucose transporter or a urea transporter.
  • the methods further comprise treating the patient with a therapeutically effective amount of the modulator of ocular surface membrane transport.
  • the modulator of ocular surface membrane transport is a CFTR agonist, a calcium-activated chloride channel activator, or an epithelial sodium channel (ENaC) inhibitor.
  • the ocular surface is the cornea. In embodiments, the ocular surface is the conjunctiva.
  • the modulator of ocular surface membrane transport is a pharmaceutical composition comprising an active agent; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof.
  • the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound A or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound B or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound C or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound D or a pharmaceutically acceptable salt thereof.
  • the active agent is Compound E or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition is a liquid pharmaceutical composition.
  • the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • the liquid pharmaceutical composition is an aqueous solution.
  • the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
  • the pharmaceutically acceptable excipient is a stabilizer, a co-solvent, or a combination thereof.
  • the disclosure provides methods of identifying a patient for treatment with a modulator of intracellular signaling.
  • the methods comprise the steps of: (i) measuring a change in an open-circuit transepithelial potential difference, in response to contact with different solutions, at an ocular surface of the patient; (ii) comparing the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, to a control; and (iii) identifying that the patient should be treated with the modulator of intracellular signaling if the change in the open-circuit transepithelial potential difference is lower than that of the control.
  • the modulator of intracellular signaling is cAMP, cGMP, or calcium signaling.
  • the modulator directly modulates intracellular signaling.
  • the modulator indirectly modulates intracellular signaling.
  • the ocular surface is the cornea or the conjunctiva.
  • the active agent is a compound of Formula (I) or a pharmaceutically acceptable salt thereof:
  • R 1 is (i) hydrogen, (ii) R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heterocycloalkyl or a substituted (e.g., with a substituent group) or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heterocycloalkyl or a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heteroaryl.
  • R 1 is hydrogen.
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted (e.g., with a substituent group) or unsubstituted C 8 - Cio heterocycloalkyl or a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heteroaryl.
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl.
  • R 1 is (i) hydrogen, (ii) R 1 and R 6 are joined to form, together with the atoms to which they are attached, an unsubstituted C 8 -Cio heterocycloalkyl or an unsubstituted C 8 -Cio heteroaryl; or (iii) R 1 and R 9 are joined to form, together with the atoms to which they are attached, an unsubstituted C 8 -Cio heterocycloalkyl or an or unsubstituted C 8 -Cio heteroaryl.
  • R 1 is (i) hydrogen, or (ii) R 1 and R 6 are joined to form, together with the atoms to which they are attached, an unsubstituted C 8 -Cio heterocycloalkyl or an unsubstituted C 8 -Cio heteroaryl.
  • the substituents for the substituted C 8 -Cio heterocycloalkyl are set forth in the definition of "substituents" (e.g., a substituent group).
  • the substituents for the substituted C 8 -Cio heterocycloalkyl are set forth in the definition of "size-limited substituent" (e.g., size-limited substituent group).
  • the substituents for the substituted C 8 -Cio heterocycloalkyl are set forth in the definition of "lower substituent” (e.g., lower substituent group).
  • the substituents for the substituted C 8 - Cio heteroaryl are set forth in the definition of "substituents” (e.g., a substituent group).
  • the substituents for the substituted C 8 -Cio heteroaryl are set forth in the definition of "size-limited substituent” (e.g., size-limited substituent group).
  • the substituents for the substituted C 8 -Cio heteroaryl are set forth in the definition of "lower substituent” (e.g., lower substituent group).
  • R 2 is a C2-C4 haloalkyl.
  • R 3 is hydrogen or a C1-C3 alkyl.
  • R 4 is hydrogen or a C1-C3 alkyl.
  • R 6 is (i) hydrogen or (ii) R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heterocycloalkyl or a substituted (e.g., with a substituent group) or
  • R 6 is hydrogen.
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heterocycloalkyl or a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heteroaryl.
  • R 9 is (i) hydrogen or (ii) R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heterocycloalkyl or a substituted (e.g., with a substituent group) or
  • R 9 is hydrogen.
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heterocycloalkyl or a substituted (e.g., with a substituent group) or unsubstituted C 8 -Cio heteroaryl.
  • the active agent is a compound of Formula (II) or a pharmaceutically acceptable salt thereof:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H. In embodiments, R 2 is -CH(CF 3 ) 2 . In embodiments, R 2 is -CH 2 CF 2 CF 2 H.
  • R 3 is hydrogen, methyl, or ethyl. In embodiments, R 3 is hydrogen. In embodiments, R 3 is methyl. In embodiments, R 3 is ethyl.
  • R 4 is hydrogen, methyl, or ethyl. In embodiments, R 4 is hydrogen. In embodiments, R 4 is methyl. In embodiments, R 4 is ethyl.
  • R 6 is hydrogen.
  • R 9 is hydrogen.
  • the active agent is a compound of Formula (III) or a pharmaceutically acceptable salt thereof:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H. In embodiments, R 2 is -CH(CF 3 ) 2 . In embodiments, R 2 is -CH 2 CF 2 CF 2 H.
  • R 3 is hydrogen, methyl, or ethyl. In embodiments, R 3 is hydrogen. In embodiments, R 3 is methyl. In embodiments, R 3 is ethyl.
  • R 4 is hydrogen, methyl, or ethyl. In embodiments, R 4 is hydrogen. In embodiments, R 4 is methyl. In embodiments, R 4 is ethyl.
  • the active agent is a compound of Formula (IV) or a pharmaceutically acceptable salt thereof:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H. In embodiments, R 2 is -CH(CF 3 ) 2 . In embodiments, R 2 is -CH 2 CF 2 CF 2 H.
  • R 4 is hydrogen, methyl, or ethyl. In embodiments, R 4 is hydrogen. In embodiments, R 4 is methyl. In embodiments, R 4 is ethyl.
  • the active agent is Compound A or a pharmaceutically acceptable salt thereof:
  • Compound A is also known as CFTRact-K267 and as ⁇ - ⁇ 1- ⁇ - ⁇ 1-6-(2,2,3,3- tetrafluoropropoxy)-l,3,5-triazine-2,4-diamine.
  • the active agent is Compound B or a pharmaceutically acceptable salt thereof:
  • the active agent is Compound C or a pharmaceutically acceptable salt
  • Compound C is also known as CFTRa Ct -K089.
  • the active agent is Compound D or a pharmaceutically acceptable salt thereof:
  • the active agent is Compound E or a pharmaceutically acceptable salt
  • the compounds described herein can be made by processes known to those skilled in the art of synthetic organic chemistry. Such exemplary processes for making the compounds described herein are set forth in WO 2017/112951, the disclosure of which is incorporated by reference herein in its entirety.
  • pharmaceutically acceptable salt is meant to include salts of the active agents that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the active agents described herein. When the active agents contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such active agents with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
  • Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
  • acid addition salts can be obtained by contacting the neutral form of such active agents with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
  • Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolyl sulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al.,
  • the neutral forms of the active agents are regenerated by contacting the salt with a base or acid and isolating the parent active agent in the conventional manner.
  • the parent form of the active agent differs from the various salt forms in certain physical properties, such as solubility in polar solvents and the like.
  • Alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di- and multivalent radicals, having the number of carbon atoms designated (i.e., C1-C10 means one to ten carbons). Alkyl is an uncyclized chain.
  • saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, (cyclohexyl)methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
  • An unsaturated alkyl group is one having one or more double bonds or triple bonds.
  • unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2- (butadienyl), 2,4-pentadienyl, 3-(l,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
  • An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (-0-).
  • alkyl refers to and includes linear or branched univalent hydrocarbon structures and combination thereof, which may be fully saturated, mono- or polyunsaturated, having the number of carbon atoms designated (i.e., C1-C10 means one to ten carbons). Particular alkyl groups are those having 1 to 20 carbon atoms (a "C1-C20 alkyl").
  • alkyl groups are those having 1 to 8 carbon atoms (a "Ci-C 8 alkyl"), 3 to 8 carbon atoms (a “C 3 -C 8 alkyl”), 1 to 6 carbon atoms (a “Ci-C 6 alkyl”), 1 to 5 carbon atoms (a “C1-C5 alkyl”), or 1 to 4 carbon atoms (a “C1-C4 alkyl”), or 1 to 3 carbon atoms (a "C1-C3 alkyl”), or 1 to 2 carbon atoms (a "C1-C2 alkyl”).
  • saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
  • An unsaturated alkyl group is one having one or more double bonds or triple bonds.
  • unsaturated alkyl groups include, but are not limited to, vinyl, 2- propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(l,4- pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
  • saturated C1-C4 alkyl examples include methyl (CH 3 ), ethyl (C2H5), propyl (C 3 H 7 ) and butyl (C4H9).
  • saturated Ci-C 6 alkyl examples include methyl (CH 3 ), ethyl (C2H5), propyl (C 3 H 7 ), butyl (C4H9), pentyl (C5H11) and hexyl (C 6 Hi 3 ).
  • An alkyl group may be substituted (i.e., one or more hydrogen atoms are replaced with univalent or divalent radicals) with one more substituents, such as radicals described herein, for example, fluoro, chloro, bromo, iodo, hydroxyl, alkoxy, thio, amino, acylamino, alkoxycarbonylamido, carboxyl, acyl, alkoxycarbonyl, sulfonyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, and other functional groups known in the art.
  • a "perfluoroalkyl” refers to an alkyl group where every hydrogen atom is replaced with a fluorine atom. Examples of saturated Ci-C 6 perfluroalkyl include trifluoromethyl (CF 3 ), pentafluoroethyl (C2F5),
  • Alkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, -CH2CH2CH2CH2-.
  • alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred.
  • a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
  • alkenylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.
  • Heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., selected from the group consisting of O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized.
  • the heteroatom(s) e.g., O, N, P, S, B, As, and Si
  • Heteroalkyl is an uncyclized chain.
  • Heteroalkyl ene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH2-CH2-S- CH2-CH2- and -CH2-S-CH2-CH2- H-CH2-.
  • heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino,
  • heteroalkyl groups include those groups that are attached to the remainder of the molecule through a heteroatom, such as -C(0)R', -C(0)NR', -NR'R", -OR, -SR, and/or -SO2R.
  • heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as -NR'R” or the like, it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR'R" or the like.
  • Cycloalkyl and heterocycloalkyl by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. Cycloalkyl and heteroalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1- cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like.
  • heterocycloalkyl examples include, but are not limited to, l-(l,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4- morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like.
  • heterocycloalkylene alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.
  • Halo or "halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as
  • haloalkyl are meant to include monohaloalkyl and polyhaloalkyl.
  • halo(Ci- C4)alkyl includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2- trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
  • Acyl means, unless otherwise stated, -C(0)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
  • Aryl means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently.
  • a fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring.
  • heteroaryl refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
  • heteroaryl includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring).
  • a 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
  • a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring.
  • a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring.
  • a heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom.
  • Non-limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazoyl benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1 -naphthyl, 2-naphthyl, 4-biphenyl, 1 -pyrrolyl, 2-pyrrolyl, 3- pyrrolyl, 3 -pyrazolyl, 2-imidazo
  • arylene and heteroarylene mean a divalent radical derived from an aryl and heteroaryl, respectively.
  • a heteroaryl group substituent may be a -O- bonded to a ring heteroatom nitrogen.
  • a "fused ring aryl-heterocycloalkyl” is an aryl fused to a heterocycloalkyl.
  • a “fused ring heteroaryl-heterocycloalkyl” is a heteroaryl fused to a heterocycloalkyl.
  • heterocycloalkyl-cycloalkyl is a heterocycloalkyl fused to a cycloalkyl.
  • heterocycloalkyl-heterocycloalkyl is a heterocycloalkyl fused to another heterocycloalkyl.
  • Fused ring aryl-heterocycloalkyl, fused ring heteroaryl-heterocycloalkyl, fused ring heterocycloalkyl- cycloalkyl, or fused ring heterocycloalkyl-heterocycloalkyl may each independently be
  • Fused ring aryl- heterocycloalkyl, fused ring heteroaryl-heterocycloalkyl, fused ring heterocycloalkyl-cycloalkyl, or fused ring heterocycloalkyl-heterocycloalkyl may each independently be named according to the size of each of the fused rings.
  • 6,5 aryl-heterocycloalkyl fused ring describes a 6 membered aryl moiety fused to a 5 membered heterocycloalkyl.
  • Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom.
  • the individual rings within spirocyclic rings may be identical or different. Individual rings in spirocyclic rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of spirocyclic rings. Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g. substituents for cycloalkyl or heterocycloalkyl rings).
  • Spirocylic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkyl ene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g. all rings being substituted heterocycloalkyl ene wherein each ring may be the same or different substituted heterocycloalkylene).
  • heterocyclic spirocyclic rings means a spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring.
  • substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.
  • oxo means an oxygen that is double bonded to a carbon atom.
  • alkyl e.g., "alkyl,” “heteroalkyl,” “aryl,” and “heteroaryl”
  • substituents for each type of radical are provided below.
  • R, R, R", R", and R" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups.
  • each of the R groups is independently selected as are each R, R", R", and R"" group when more than one of these groups is present.
  • R and R" When R and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring.
  • - R'R includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl.
  • alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF 3 and -CH 2 CF 3 ) and acyl (e.g., -C(0)CH 3 , -C(0)CF 3 , -C(0)CH 2 OCH 3 , and the like).
  • each of the R groups is independently selected as are each R, R", R", and R"" groups when more than one of these groups is present.
  • Substituents for rings e.g. cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroaryl ene
  • substituents on the ring may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent).
  • the substituent may be attached to any of the ring atoms (obeying the rules of chemical valency) and in the case of fused rings or spirocyclic rings, a substituent depicted as associated with one member of the fused rings or spirocyclic rings (a floating substituent on a single ring), may be a substituent on any of the fused rings or spirocyclic rings (a floating substituent on multiple rings).
  • the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different spirocyclic rings, and each substituent may optionally be different.
  • a point of attachment of a ring to the remainder of a molecule is not limited to a single atom (a floating substituent)
  • the attachment point may be any atom of the ring and in the case of a fused ring or spirocyclic ring, any atom of any of the fused rings or spirocyclic rings while obeying the rules of chemical valency.
  • a ring, fused rings, or spirocyclic rings contain one or more ring heteroatoms and the ring, fused rings, or spirocyclic rings are shown with one more floating substituents (including, but not limited to, points of attachment to the remainder of the molecule), the floating substituents may be bonded to the heteroatoms.
  • the ring heteroatoms are shown bound to one or more hydrogens (e.g. a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with the floating substituent, when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen, while obeying the rules of chemical valency.
  • Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
  • Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure.
  • the ring-forming substituents are attached to adjacent members of the base structure.
  • two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure.
  • the ring-forming substituents are attached to a single member of the base structure.
  • two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure.
  • the ring-forming substituents are attached to non-adjacent members of the base structure.
  • Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(0)-(CRR') q -U-, wherein T and U are independently - R-, -0-, - CRR'-, or a single bond, and q is an integer of from 0 to 3.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r -B-, wherein A and B are independently -CRR'-, -0-, - R-, -S-, -S(O) -, -S(0) 2 -, - S(0) 2 R'-, or a single bond, and r is an integer of from 1 to 4.
  • One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
  • two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -(CRR')s-X'- (C"R"R"')d-, where s and d are independently integers of from 0 to 3, and X' is -0-, - R'-, -S-, -S(O)-, -S(0) 2 -, or -S(0) 2 R'-.
  • R, R', R", and R' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
  • heteroatom or "ring heteroatom” are meant to include, oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), Boron (B), Arsenic (As), and silicon (Si).
  • a "size-limited substituent” or " size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a "substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-C 2 o alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -Cio aryl, and each substituted or unsubstituted heteroary
  • a "lower substituent” or “lower substituent group,” as used herein, means a group selected from all of the substituents described above for a "substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-Cs alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -Cio aryl, and each substituted or unsubstituted heteroaryl is a
  • each substituted group described in the active agents herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the active agents herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted
  • heterocycloalkylene, substituted arylene, and/or substituted heteroarylene is substituted with at least one substituent group, wherein if the substituted moiety is substituted with a plurality of substituent groups, each substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of substituent groups, each substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkyl ene, substituted cycloalkylene, substituted
  • heterocycloalkylene, substituted arylene, and/or substituted heteroarylene is substituted with at least one size-limited substituent group, wherein if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkyl ene, substituted cycloalkylene, substituted
  • heterocycloalkylene, substituted arylene, and/or substituted heteroarylene is substituted with at least one lower substituent group, wherein if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group may optionally be different.
  • each lower substituent group is different.
  • a substituted moiety e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkyl ene, substituted cycloalkylene, substituted
  • heterocycloalkylene, substituted arylene, and/or substituted heteroarylene is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size- limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group is different.
  • each substituted or unsubstituted alkyl may be a substituted or unsubstituted C1-C20 alkyl
  • each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl
  • each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl
  • each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl
  • each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -Cio aryl
  • each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
  • each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C20 alkylene
  • each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene
  • each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene
  • each substituted or unsubstituted or unsubstituted alkylene is a substituted or unsubstituted C1-C20 alkylene
  • each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene
  • each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene
  • heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene
  • each substituted or unsubstituted arylene is a substituted or unsubstituted C 6 -Cio arylene
  • each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroaryl ene.
  • each substituted or unsubstituted alkyl is a substituted or unsubstituted Ci-Cs alkyl
  • each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl
  • each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl
  • each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl
  • each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -Cio aryl
  • each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.
  • each substituted or unsubstituted alkylene is a substituted or unsubstituted Ci-Cs alkylene
  • each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene
  • each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C7 cycloalkylene
  • each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene
  • each substituted or unsubstituted arylene is a substituted or unsubstituted C 6 -Cio arylene
  • each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene.
  • the active agent is a chemical species set forth in the Examples section, figures, or tables below
  • Certain active agents described herein possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)-or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the disclosure.
  • the disclosure includes active agents in racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
  • the active agents described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the active agents include both E and Z geometric isomers.
  • tautomer refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another. It will be apparent to one skilled in the art that certain active agents may exist in tautomeric forms, all such tautomeric forms of the active agents being within the scope of the disclosure.
  • CFTR cystic fibrosis transmembrane conductance regulator
  • CFTR cystic fibrosis transmembrane conductance regulator
  • corneal and conjunctival epithelial cells as well as in various secretory epithelia outside of the eye.
  • CFTR activation drives fluid secretion by epithelial cells lining the ocular surface
  • augmentation of tear fluid does not require functional lacrimal or Meibomian glands.
  • the inventors identified by high-throughput screening an aminophenyl-l,3,5-triazine class of small molecule activators of wildtype CFTR.
  • a compound from the screen, Compound A fully activated CFTR in cell cultures with EC50 of about 250 nM, and, when delivered topically to mice, doubled tear volume for four hours. (Reference 14).
  • Compound C administered three times daily, normalized tear volume, prevented corneal epithelial disruption, and even reversed pathology when administered after development of dry eye.
  • Compound A was synthesized by stepwise substitution reactions of cyanuric chloride with methylamine, 2,2,3, 3-tetrafluoropropanol, and aniline under basic conditions, as described in Reference 15, and purified to >95% by flash chromatography (1 :2 ethyl acetate:hexane).
  • Compound A was prepared as a 10 mM dimethyl sulfoxide (DMSO) stock solution.
  • DMSO dimethyl sulfoxide
  • CMC carboxymethylcellulose
  • BAC benzalkonium chloride
  • Open-circuit transepithelial potential difference (PD, in mV) at the ocular surface was measured continuously in anesthetized rabbits using a procedure modified from that established in mice. (Reference 8). Rabbits were intubated and anesthetized with isoflurane, and respiratory rate, blood pressure and body temperature were monitored. For PD recording, solutions (see below) were serially perfused at 10 mL/min through PE-90 plastic tubing using a gravity multi -reservoir pinch- valve system (ALA Scientific, Westbury, NY) and a variable-flow peristaltic pump (medium flow model; Thermo Fisher Scientific, Fair Lawn, NJ).
  • a probe catheter was fixed onto an adjustable stereotaxic frame with the tip immersed in solution contacting the ocular surface.
  • Excess fluid was aspirated by continuous suction (low-powered wall vacuum) using 1/8-inch tubing (inner diameter 3/32 inch) positioned 3 mm from the orbit in order to maintain near-constant perfusate volume in contact with cornea, bulbar conjunctiva and palpebral conjunctiva without fluid runoff.
  • the measuring electrode contacted the perfusion catheter and was connected to a high-impedance voltmeter (IsoMilivolt Meter; World Precision Instruments, Sarasota, FL).
  • the reference electrode was grounded using a winged, 25-gauge needle filled with normal saline inserted subcutaneously in the abdomen.
  • the measuring and reference electrodes consisted of Ag/AgCl with 3 M KC1 agar bridges.
  • Solutions consisted of: i) Normal CI " solution (mM): 99 NaCl, 24 KC1, 32 NaHCOs, 1.0 NaH 2 P0 4 , 0.6 MgCl 2 , 0.8 CaCl 2 ; ii) Normal CI " solution with amiloride (100 ⁇ ); iii) Low CI " solution with amiloride (NaCl replaced by Na gluconate and KC1 by K gluconate); iv) Low CI “ + amiloride + Compound A (1 ⁇ ); v) Low CI “ + amiloride + Compound A (10 ⁇ ); vi) Low CI " + amiloride + Compound A (10 ⁇ ) + forskolin (FSK, 20 ⁇ ); vii) Low CI " + amiloride + FSK + Compound A (10 ⁇ ) + CFTR in h-172 (3-[(3-Trifluoromethyl)phenyl]-5-[(4- carboxyphenyl)methylene]-2-thio
  • Schirmer Tear Test II Tear production was measured using the anesthetized Schirmer Tear Test (STT, Eagle Vision, Memphis TN). To minimize reflex tearing, one drop of 0.5% proparacaine
  • hydrochloride (Akorn, Lake Forest, IL) was placed onto the corneal surface and excess fluid was absorbed at the medial canthus using eye spear sponges (Fine Science Tools, Foster City, CA). After 5 min the notched strip was inserted into the lower lateral conjunctival fornix, maintaining contact with the lateral cornea. The wetted length (mm) of the strip indicated by blue dye appearance was read after 5 min.
  • Compound A was quantified by liquid chromatography/mass spectroscopy (LC/MS) at 15 min, 1 hour, 2 hours, 6 hours and 24 hours after a single, 3-nmol topical dose.
  • LC/MS liquid chromatography/mass spectroscopy
  • Lissamine green strips (GreenGlo, HUB Pharmaceuticals LLC, Collinso Cucamonga, CA) were wetted with 25 mL lubricant eye drops and then applied gently into the inferior fornix.
  • photographs of the eye were taken with a digital camera and staining was evaluated according to a 12-point scale as described 17 : each corneal quadrant was scored in a blinded fashion on a 3- point scale: grade 0, no staining; grade 1, sporadic staining (involving ⁇ 25% of the total surface); grade 2, diffuse punctate staining (25-75%); and grade 3, coalesced punctate staining (>75%).
  • the total grade is reported as the sum of scores from all 4 quadrants, ranging from 0 to 12.
  • Compound A activates CFTR chloride conductance at the rabbit ocular surface.
  • Compound A activity at the ocular surface in rabbits in vivo was measured using an open-circuit potential difference (PD) method, as developed originally in mice. The method involves perfusion of the ocular surface with a series of solutions during continuous
  • the representative PD curve in Fig. 2A shows an initial depolarization following addition of the ENaC inhibitor amiloride, with hyperpolarizations following perfusion with low CI " solutions without and then with Compound A, and then with a high concentration of the cAMP agonist forskolin to maximally activate CFTR.
  • the CFTR inhibitor CFTRinh-1 2 was present in the final perfusion solution.
  • ocular surface PD data should be considered semi-quantitative because of non-linearity in PD values with CFTR function, and because of uncertainties in the extent of perfusate fluid contact with whole ocular surface and of compound accumulation in ocular surface cells.
  • CFTR activation was measured in freshly isolated conjunctiva ex vivo by short-circuit current analysis.
  • the representative curve in Fig. 2C shows a small increase in current in response to addition of a low concentration of forskolin (25 nM), which was further increased by 1 and then 10 ⁇ Compound A.
  • Maximal CFTR activation was produced by a high concentration of forskolin.
  • the increases in short-circuit current were inhibited by CFTRinh-172.
  • Amiloride (10 ⁇ ) had no effect on short-circuit current (not shown). Averaged changes in short-circuit current are summarized in Fig. 2D.
  • Compound A was tested for its efficacy in augmenting tear fluid production in rabbits.
  • Prior work identified a formulation (0.325% CMC in Ringer's solution containing 0.015% BAC and 1%) DMSO) that stably solubilized Compound A and was effective when delivered topically to mice.
  • 15 A single application of 3 nmol Compound A (10 ⁇ _, of a 100 ⁇ solution) increased tear volume by -60% for at least 9 hours compared to vehicle (Fig. 3 A).
  • Dose-dependence studies showed similar activity of 6 nmol Compound A, but reduced duration of activity with 1.5 nmol Compound A and no significant increase in tear production with 0.75 nmol Compound A (Fig. 3B).
  • 3 nmol of Compound A was delivered in a more viscous formulation containing 0.625%) (instead of 0.3%>) CMC, to potentially increase Compound A ocular surface residence time, compound efficacy was unchanged (Fig. 3C).
  • Fig. 4A shows original LC/MS data and a standard curve from which the amount of recovered Compound A was deduced.
  • Fig. 4B shows an approximate exponential decline in Compound A recovered from tear fluid (closed circles, left axis).
  • Corresponding compound concentrations in tear fluid were estimated using tear volumes deduced from STT measurements in Fig. 2A.
  • the PD results here in rabbits showed rapid CFTR activation at the ocular surface with maximal effects within a few minutes after exposure to Compound A. Because of its simplicity and good signal-to-noise, measurements of ocular surface PD may be translatable to humans as a surrogate functional assay of drug candidates targeting ion channels.
  • Another pro-secretory strategy for increasing tear fluid is anti-absorptive therapy by inhibition of ENaC sodium channels.
  • ENaC sodium channels In a phase I/IIa study the ENaC inhibitor P321 has shown tolerability and safety in patients with mild to moderate dry eye (Reference 29), and a phase II study is in progress.
  • Theoretical modeling supports the efficacy of an anti-absorptive approach to increase tear fluid, albeit with lower efficacy than a pro-secretory approach; modeling also supports the additive action of anti-absorptive and pro-secretory drugs. (Reference 19).
  • pro- secretory or anti-absorption drugs are combinable with anti-inflammatory drugs because they target distinct mechanisms in dry eye pathogenesis.
  • pro-secretory or anti- absorptive therapy may not correct lipid or mucin deficiency in some cases of dry eye; however, augmentation of aqueous volume is predicted to correct tear fluid hyperosmolality and downstream inflammation even in evaporative dry eye.
  • Compound A may thus be a safe and effective therapy of human dry eye disorders, alone or when combined with other dry eye medications.
  • Embodiment PI A method of increasing tear production in an eye of a patient in need thereof, the method comprising topically administering to the eye of the patient a pharmaceutical composition comprising about 5 micrograms or more of an active agent to increase tear production; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • Embodiment P2 A method of treating a dry eye disease in a patient in need thereof, the method comprising topically administering to an eye of the patient a pharmaceutical composition comprising about 5 micrograms or more of an active agent to treat the dry eye disease; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • Embodiment P3 The method of embodiment PI or P2, wherein the pharmaceutical composition comprises from about 5 micrograms to about 100 micrograms of the active agent.
  • Embodiment P4 The method of embodiment PI or P2, wherein the pharmaceutical composition comprises from about 5 micrograms to about 50 micrograms of the active agent.
  • Embodiment P5 The method of embodiment PI or P2, wherein the pharmaceutical composition comprises from about 5 micrograms to about 35 micrograms of the active agent.
  • Embodiment P6 The method of embodiment PI or P2, wherein the pharmaceutical composition comprises about 10 micrograms of the active agent.
  • Embodiment P7 A method of increasing tear production in an eye of a patient in need thereof, the method comprising topically administering to the eye of the patient a pharmaceutical composition comprising about 2 nanomoles or more of an active agent to increase tear production; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • Embodiment P8 A method of treating a dry eye disease in a patient in need thereof, the method comprising topically administering to an eye of the patient a pharmaceutical composition comprising about 2 nanomoles or more of an active agent to treat the dry eye disease; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B,
  • Embodiment P9 The method of embodiment P7 or P8, wherein the pharmaceutical composition comprises from about 2 nanomoles to about 50 nanomoles of the active agent.
  • Embodiment P10 The method of embodiment P7 or P8, wherein the pharmaceutical composition comprises from about 2 nanomoles to about 25 nanomoles of the active agent.
  • Embodiment PI 1 The method of embodiment P7 or P8, wherein the pharmaceutical composition comprises from about 2 nanomoles to about 10 nanomoles of the active agent.
  • Embodiment P12 The method of embodiment P7 or P8, wherein the pharmaceutical composition comprises about 3 nanomoles of the active agent.
  • Embodiment P 13 A method of increasing tear production in an eye of a patient in need thereof, the method comprising topically administering to the eye of the patient a pharmaceutical composition comprising a therapeutically effective amount of an active agent to increase tear production; wherein the therapeutically effective amount provides a concentration of the active agent in an amount of about 500 nM or more in the tear fluid of the eye about 1 hour to about 12 hours after administration; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • a pharmaceutical composition comprising a therapeutically effective amount of an active agent to increase tear production; wherein the therapeutically effective amount provides a concentration of the active agent in an amount of about 500 nM or more in the tear fluid of the eye about 1 hour to about 12 hours after administration; wherein the active agent is a compound of Formula (I
  • Embodiment P14 A method of treating a dry eye disease in a patient in need thereof, the method comprising topically administering to an eye of the patient a pharmaceutical composition comprising a therapeutically effective amount of an active agent to treat the dry eye disease; wherein the therapeutically effective amount provides a concentration of the active agent in an amount of (i) about 500 nM or more in the tear fluid of the eye about 30 minutes to about 3 hours after administration, or (ii) about 10 nM or more in the tear fluid of the eye about 4 hours to about to about 12 hours after administration; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a
  • Embodiment PI 5 The method of embodiment P13 or PI 4, wherein the therapeutically effective amount of the active agent provides a concentration of (i) about 500 nM to about 5,000 nM about 1 hour to about 3 hours after administration, or (ii) about 10 nM to about 2,000 nM about 4 hours to about 8 hours after administration.
  • Embodiment P16 The method of embodiment P13 or P14, wherein the therapeutically effective amount of the active agent provides a concentration of (i) about 500 nM to about 1,500 nM about 1 hour to about 3 hours after administration, or (ii) about 50 nM to about 500 nM about 5 hours to about 7 hours after administration.
  • Embodiment P17 The method of embodiment P13 or P14, wherein the therapeutically effective amount of the active agent provides a concentration of (i) about 1000 nM about 2 hours after administration, or (ii) about 100 nM about 6 hours after administration.
  • Embodiment PI 8 A method of increasing tear production in an eye of a patient in need thereof, the method comprising topically administering once per day or twice per day to the eye of the patient a pharmaceutical composition comprising of an active agent to increase tear production; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • Embodiment PI 9 A method of treating a dry eye disease in a patient in need thereof, the method comprising topically administering once per day or twice per day to an eye of the patient a pharmaceutical composition comprising an active agent to treat the dry eye disease; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B,
  • Embodiment P20 The method of any one of embodiments PI to PI 9, wherein the pharmaceutical composition is a liquid pharmaceutical composition.
  • Embodiment P21 The method of embodiment P20, wherein the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • Embodiment P22 The method of embodiment P20, wherein the liquid pharmaceutical composition is an aqueous solution.
  • Embodiment P23 The method of embodiment P20, wherein the liquid pharmaceutical composition is a suspension; and wherein the active agent is micronized.
  • Embodiment P24 The method of any one of embodiments PI to 2P3, wherein the active agent is the compound of Formula (I) or the pharmaceutically acceptable salt thereof.
  • Embodiment P25 The method of any one of embodiments PI to P23, wherein the active agent is the compound of Formula (II) or the pharmaceutically acceptable salt thereof.
  • Embodiment P26 The method of any one of embodiments PI to P23, wherein the active agent is the compound of Formula (III) or the pharmaceutically acceptable salt thereof.
  • Embodiment P27 The method of any one of embodiments PI to P23, wherein the active agent is the compound of Formula (IV) or the pharmaceutically acceptable salt thereof
  • Embodiment P28 The method of any one of embodiments PI to P23, wherein the active agent is Compound A or the pharmaceutically acceptable salt thereof.
  • Embodiment P29 The method of any one of embodiments PI to P23, wherein the active agent is Compound B or the pharmaceutically acceptable salt thereof.
  • Embodiment P30 The method of any one of embodiments PI to P23, wherein the active agent is Compound C or the pharmaceutically acceptable salt thereof
  • Embodiment P31 The method of any one of embodiments PI to P23, wherein the active agent is Compound D or the pharmaceutically acceptable salt thereof.
  • Embodiment P32 The method of any one of embodiments PI to P23, wherein the active agent is Compound E or the pharmaceutically acceptable salt thereof.
  • Embodiment P33 The method of any one of embodiments PI to P32 wherein the composition further comprises a pharmaceutically acceptable excipient.
  • Embodiment P34 The method of embodiment P33, wherein the pharmaceutically acceptable excipient is a stabilizer, a co-solvent, or a combination thereof.
  • Embodiment P35 The method of any one of embodiments PI to P34, comprising topically administering the pharmaceutical composition to the conjunctiva of the eye.
  • Embodiment P36 The method of any one of embodiments PI to P34 comprising topically administering the pharmaceutical composition to the conjunctival sac of the eye.
  • Embodiment P37 The method of any one of embodiments PI to P36, wherein the pharmaceutical composition is administered once per day.
  • Embodiment P38 The method of any one of embodiments PI to P36, wherein the pharmaceutical composition is administered twice per day.
  • Embodiment P39 The method of any one of embodiments PI to P38, wherein the composition is administered for about 14 days.
  • Embodiment P40 The method of any one of embodiments PI to P38, wherein the composition is administered for about one month.
  • Embodiment P41 The method of any one of embodiments PI to P40, further comprising administering a epithelial sodium channel inhibitor, a lymphocyte function- associated antigen-1 antagonist, an anti-inflammatory agent, a cholinergic agonist, a steroid, an antibiotic, or a combination of two or more thereof.
  • Embodiment P42 The method of embodiment 41, wherein the epithelial sodium channel inhibitor is amiloride; wherein the lymphocyte function-associated antigen-1 antagonist is lifitegrast; wherein the anti-inflammatory agent is cyclosporine; wherein the cholinergic agonist is pilocarpine or cevimeline; and wherein the steroid is a corticosteroid.
  • the epithelial sodium channel inhibitor is amiloride
  • the lymphocyte function-associated antigen-1 antagonist is lifitegrast
  • the anti-inflammatory agent is cyclosporine
  • the cholinergic agonist is pilocarpine or cevimeline
  • the steroid is a corticosteroid.
  • Embodiment P43 The method of any one of embodiments PI to P42, wherein the patient is a human.
  • Embodiment P44 The method of any one of embodiments PI to P43, wherein the patient has an open-circuit transepithelial potential difference, in response to contact with different solutions, that is lower than that of a control.
  • Embodiment P45 The method of any one of embodiments PI to P44, further comprising testing the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, at the surface of the eye of the patient, and comparing the result to a control.
  • Embodiment P46 A topical pharmaceutical composition comprising about 5 micrograms or more of an active agent and a pharmaceutically acceptable carrier; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • Embodiment P47 The composition of embodiment P46, comprising from about 5 micrograms to about 1 gram of the active agent.
  • Embodiment P48 The composition of embodiment P46, comprising from about 5 micrograms to about 1 milligram of the active agent.
  • Embodiment P49 The composition of embodiment P46, comprising from about 5 micrograms to about 500 micrograms.
  • Embodiment P50 The composition of embodiment P46, comprising from about 5 micrograms to about 35 micrograms of the active agent.
  • Embodiment P51 The composition of embodiment P47, comprising about 10 micrograms.
  • Embodiment P52 A topical pharmaceutical composition comprising from about 1 nanomole to about 25 nmoles per 0.5 mL of an active agent and a pharmaceutically acceptable excipient; wherein the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • the active agent is a compound of Formula (I), a compound of Formula (II), a compound of Formula (III), a compound of Formula (IV), Compound A, Compound B, Compound C, Compound D, Compound E, or a pharmaceutically acceptable salt of any of the foregoing.
  • Embodiment P53 The composition of embodiment P52, comprising from about 1 nanomole to about 15 nmoles per 0.5 mL of the active agent.
  • Embodiment P54 The composition of embodiment P52, comprising from about 2 nanomoles to about 10 nmoles per 0.5 mL of the active agent.
  • Embodiment P55 The composition of embodiment P52, comprising about 3 nanomoles per 0.5 mL of the active agent.
  • Embodiment P56 The composition of any one of embodiments P46 to P55, wherein the topical pharmaceutical composition is a liquid pharmaceutical composition.
  • Embodiment P57 The composition of embodiment P56, wherein the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • Embodiment P58 The composition of embodiment P56, wherein the liquid pharmaceutical composition is an aqueous solution.
  • Embodiment P59 The composition of embodiment P56, wherein the liquid pharmaceutical composition is a suspension; and wherein the compound is micronized.
  • Embodiment P60 The composition of any one of embodiments P46 to P59, wherein the composition further comprises a pharmaceutically acceptable excipient.
  • Embodiment P61 The composition of embodiment P60, wherein the pharmaceutically acceptable excipient is a stabilizer, a co-solvent, or a combination thereof.
  • Embodiment P62 The composition of any one of embodiments P46 to P61, wherein the active agent is the compound of Formula (I) or the pharmaceutically acceptable salt thereof.
  • Embodiment P63 The composition of any one of embodiments P46 to P61, wherein the active agent is the compound of Formula (II) or the pharmaceutically acceptable salt thereof.
  • Embodiment P64 The composition of any one of embodiments P46 to P61, wherein the active agent is the compound of Formula (III) or the pharmaceutically acceptable salt thereof.
  • Embodiment P65 The composition of any one of embodiments P46 to P61, wherein the pharmaceutical composition comprises the compound of Formula (IV) or the pharmaceutically acceptable salt thereof.
  • Embodiment P66 The composition of any one of embodiments P46 to P61, wherein the active agent is Compound A or the pharmaceutically acceptable salt thereof.
  • Embodiment P67 The composition of any one of embodiments P46 to P61, wherein the active agent is Compound B or the pharmaceutically acceptable salt thereof.
  • Embodiment P68 The composition of any one of embodiments P46 to P61, wherein the active agent is Compound C or the pharmaceutically acceptable salt thereof.
  • Embodiment P69 The composition of any one of embodiments P46 to P61, wherein the active agent is Compound D or the pharmaceutically acceptable salt thereof.
  • Embodiment P70 The composition of any one of embodiments P46 to P61, wherein the active agent is Compound E or the pharmaceutically acceptable salt thereof.
  • Embodiment P71 An eye dropper for delivering a drop of a topical pharmaceutical composition to the eye of a patient; wherein the eye dropper comprises the topical composition of any one of embodiments P46 to P70.
  • Embodiment P72 The eye dropper of embodiment P71 having a volume sufficient to house 1 to 25 drops of the composition.
  • Embodiment P73 The eye dropper of embodiment P71 having a volume sufficient to house 1 to 15 drops of the composition.
  • Embodiment P74 The eye dropper of embodiment PI having a volume sufficient to house 1 to 10 drops of the composition.
  • Embodiment P75 A kit comprising the eye dropper of any one of embodiments P71 to P74 and instructions for use.
  • Embodiment P76 The kit of embodiment P75, comprising seven eye droppers, fourteen eye droppers, twenty-eight eye droppers, or fifty-six eye droppers.
  • Embodiment P77 A kit comprising an eye dropper, a container which comprises the topical pharmaceutical composition of any one of embodiments P46 to P70, and instructions for use.
  • Embodiment P78 The kit of embodiment P77, comprising one eye dropper and one container; wherein the container comprises one dose of the composition.
  • Embodiment P79 The kit of embodiment P77, comprising two eye droppers and one container; wherein the container comprises two doses of the composition.
  • Embodiment P80 The kit of embodiment P77, comprising two eye droppers and two containers; wherein each container comprises one dose of the composition.
  • Embodiment P81 The kit of embodiment P77, comprising seven eye droppers and seven containers; wherein each container comprises one dose of the composition.
  • Embodiment P82 The kit of embodiment P77, comprising fourteen eye droppers and seven containers; wherein each container comprises two doses of the composition.
  • Embodiment P83 The kit of embodiment P77, comprising fourteen eye droppers and fourteen containers; wherein each container comprises one dose of the
  • Embodiment P84 A method of identifying a patient for treatment with a modulator of ocular surface membrane transport, the method comprising the steps of:
  • Embodiment P85 The method of embodiment P84, wherein the ocular surface membrane transport is an ion transporter or a biomolecule transporter.
  • Embodiment P86 The method of embodiment P85, wherein the ion transporter is a chloride transporter, a potassium transporter, or a bicarbonate transporter; and wherein the biomolecule transporter is a glucose transporter or a urea transporter.
  • the ion transporter is a chloride transporter, a potassium transporter, or a bicarbonate transporter
  • the biomolecule transporter is a glucose transporter or a urea transporter.
  • Embodiment P87 The method of embodiment P85, further comprising treating the patient with a therapeutically effective amount of the modulator of ocular surface membrane transport.
  • Embodiment P88. The method of embodiment P85, wherein the modulator of ocular surface membrane transport is a CFTR agonist, a calcium-activated chloride channel activator, or an epithelial sodium channel (ENaC) inhibitor.
  • Embodiment P89 The method of embodiment P85, wherein the modulator of ocular surface membrane transport is a pharmaceutical composition of any one of claims 46 to 70.
  • Embodiment P90 A method of identifying a patient for treatment with a modulator of intracellular signaling, the method comprising the steps of:
  • Embodiment P91 The method of embodiment P90, wherein the modulator of intracellular signaling is cAMP, cGMP, or calcium signaling; wherein the modulator directly or indirectly modulates intracellular signaling.
  • Embodiment P92 The method of embodiment P90, further comprising treating the patient by administering a therapeutically effective amount of the pharmaceutical composition of any one of claims 46 to 70.
  • Embodiment P93 The method of any one of embodiments P84 to P92, wherein the ocular surface is the cornea or the conjunctiva.
  • Embodiment 1 A method of treating a patient in need of increased tear production comprising topically administering to an eye of the patient at least about 5 micrograms of at least one compound selected from a group consisting of:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -C io heteroaryl; or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is a C2-C4 haloalkyl
  • R 3 is hydrogen or a C 1-C3 alkyl
  • R 4 is hydrogen or a C 1-C3 alkyl
  • R 6 is:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 9 is:
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 6 is:
  • R 9 is:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 4 is hydrogen, methyl, or ethyl
  • Embodiment 2 A method of treating a dry eye disease in a patient comprising topically administering to an eye of the patient at least about 5 micrograms of at least one active agent selected from a group consisting of:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl; or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is a C2-C4 haloalkyl
  • R 3 is hydrogen or a C1-C3 alkyl
  • R 4 is hydrogen or a C1-C3 alkyl
  • R 6 is:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 9 is:
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 6 is: (i) hydrogen; or
  • R 9 is:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 4 is hydrogen, methyl, or ethyl
  • Embodiment 3 The method of embodiment 1 or 2, wherein the method comprises administering from about 5 micrograms to about 100 micrograms of the active agent.
  • Embodiment 4 The method of embodiment 1 or 2, wherein the method comprises administering from about 5 micrograms to about 50 micrograms of the active agent.
  • Embodiment 5 The method of embodiment 1 or 2, wherein the method comprises administering from about 5 micrograms to about 35 micrograms of the active agent.
  • Embodiment 6 The method of embodiment 1 or 2, wherein the method comprises administeringa about 10 micrograms of the active agent.
  • Embodiment 7. A method of treating a patient in need of increased tear production comprising: topically administering to an eye of the patient at least about 2 nanomoles of at least one active agent selected from a group consisting of:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl; or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is a C2-C4 haloalkyl
  • R 3 is hydrogen or a C1-C3 alkyl
  • R 4 is hydrogen or a C1-C3 alkyl
  • R 6 is:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 9 is:
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 6 is:
  • R 9 is:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 4 is hydrogen, methyl, or ethyl
  • Embodiment 8 A method of treating a patient with dry eye disease comprising: topically administering to an eye of the patient at least about 2 nanomoles of at least active agent selected from a group consisting of:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl; or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is a C2-C4 haloalkyl
  • R 3 is hydrogen or a C1-C3 alkyl
  • R 4 is hydrogen or a C1-C3 alkyl
  • R 6 is:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 9 is:
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 6 is: (i) hydrogen; or
  • R 9 is:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 4 is hydrogen, methyl, or ethyl
  • Embodiment 9 The method of embodiment 7 or 8, wherein the method comprises administering from about 2 nanomoles to about 50 nanomoles of the active agent.
  • Embodiment 10 The method of embodiment 7 or 8, wherein the method comprises administering from about 2 nanomoles to about 25 nanomoles of the active agent.
  • Embodiment 11 The method of embodiment 7 or 8, wherein the method comprises administeringf rom about 2 nanomoles to about 10 nanomoles of the active agent.
  • Embodiment 12 The method of embodiment 7 or 8, wherein the method comprises administeringa about 3 nanomoles of the active agent.
  • Embodiment 13 A method of treating a patient in need of increased tear production comprising: topically administering to an eye of the patient an amount of an active agent producing a concentration of about 500 nM or more in the tear fluid of the eye about 1 hour to about 12 hours after administration; wherein the active agent is selected from a group consisting of:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl; or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is a C2-C4 haloalkyl
  • R 3 is hydrogen or a C1-C3 alkyl
  • R 4 is hydrogen or a C1-C3 alkyl
  • R 6 is:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 9 is:
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 6 is:
  • R 9 is:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 4 is hydrogen, methyl, or ethyl
  • Embodiment 14 A method of treating a patient with dry eye disease comprising: topically administering to an eye of the patient an amount of an active agent producing (i) about 500 nM or more in the tear fluid of the eye about 30 minutes to about 3 hours after administration, or (ii) about 10 nM or more in the tear fluid of the eye about 4 hours to about to about 12 hours after administration; wherein the active agent is selected from a group consisting of:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl; or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is a C2-C4 haloalkyl
  • R 3 is hydrogen or a C1-C3 alkyl
  • R 4 is hydrogen or a C1-C3 alkyl
  • R 6 is:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 9 is:
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl;
  • R 4 is hydrogen, methyl, or ethyl
  • R 6 is:
  • R 9 is:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • Embodiment 15 The method of embodiment 13 or 14, wherein the
  • therapeutically effective amount of the active agent provides a concentration of (i) about 500 nM to about 5,000 nM about 1 hour to about 3 hours after administration, or (ii) about 10 nM to about 2,000 nM about 4 hours to about 8 hours after administration.
  • Embodiment 16 The method of embodiment 13 or 14, wherein the
  • therapeutically effective amount of the active agent provides a concentration of (i) about 500 nM to about 1,500 nM about 1 hour to about 3 hours after administration, or (ii) about 50 nM to about 500 nM about 5 hours to about 7 hours after administration.
  • Embodiment 17 The method of embodiment 13 or 14, wherein the
  • a method of increasing tear production in an eye of a patient in need thereof comprising topically administering once per day or twice per day to the eye of the patient at least one active agent selected from a group consisting of:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl; or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is a C2-C4 haloalkyl
  • R 3 is hydrogen or a C1-C3 alkyl
  • R 4 is hydrogen or a C1-C3 alkyl
  • R 6 is:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 9 is:
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 6 is:
  • R 9 is:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 4 is hydrogen, methyl, or ethyl
  • compound B having the formula: ⁇ , or a pharmaceutically acceptable salt thereof
  • compound C having the formula:
  • Embodiment 19 A method of treating a patient with a dry eye disease comprising: topically administering once or twice per day to an eye of the patient an amount of at least one active agent effective to treat the dry eye disease; wherein the active agent is selected from a group consisting of:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl; or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is a C2-C4 haloalkyl
  • R 3 is hydrogen or a C1-C3 alkyl
  • R 4 is hydrogen or a C1-C3 alkyl
  • R 6 is:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 9 is:
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 6 is:
  • R 9 is:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 4 is hydrogen, methyl, or ethyl; compound A having the formula:
  • Embodiment 20 The method of any one of embodiments 1 to 19, wherein the active agent is the compound of Formula (I) or the pharmaceutically acceptable salt thereof.
  • Embodiment 21 The method of any one of embodiments 1 to 19, wherein the active agent is the compound of Formula (II) or the pharmaceutically acceptable salt thereof.
  • Embodiment 22 The method of any one of embodiments 1 to 19, wherein the active agent is the compound of Formula (III) or the pharmaceutically acceptable salt thereof.
  • Embodiment 23 The method any one of embodiments 1 to 19, wherein the active agent is the compound of Formula (IV) or the pharmaceutically acceptable salt thereof.
  • Embodiment 24 The method of any one of embodiments 1 to 19, wherein the active agent is Compound A or the pharmaceutically acceptable salt thereof.
  • Embodiment 25 The method of any one of embodiments 1 to 19, wherein the active agent is Compound B or the pharmaceutically acceptable salt thereof.
  • Embodiment 26 The method of any one of embodiments 1 to 19, wherein the active agent is Compound C or the pharmaceutically acceptable salt thereof.
  • Embodiment 27 The method of any one of embodiments 1 to 19, wherein the active agent is Compound D or the pharmaceutically acceptable salt thereof.
  • Embodiment 28 The method of any one of embodiments 1 to 19, wherein the active agent is Compound E or the pharmaceutically acceptable salt thereof.
  • Embodiment 29 The method of any one of embodiments 1 to 28, comprising topically administering the active agent to the conjunctiva of the eye.
  • Embodiment 30 The method of any one of embodiments 1 to 28, comprising topically administering the active agent to the conjunctival sac of the eye.
  • Embodiment 31 The method of any one of embodiments 1 to 30, wherein the active agent is administered once per day.
  • Embodiment 32 The method of any one of embodiments 1 to 30, wherein the active agent is administered twice per day.
  • Embodiment 33 The method of any one of embodiments 1 to 30, wherein the active agent is administered for about 14 days.
  • Embodiment 34 The method of any one of embodiments 1 to 30, wherein the active agent is administered for about one month.
  • Embodiment 35 The method of any one of embodiments 1 to 34, further comprising: co-administering one or more additional therapeutic agents in amounts effective to enhance the therapeutic effects of the active agent, wherein the additional therapeutic agents are selected from a group consisting of: an epithelial sodium channel inhibitor, a lymphocyte function- associated antigen- 1 antagonist, an anti-inflammatory agent, a cholinergic agonist, a steroid, and an antibiotic.
  • the additional therapeutic agents are selected from a group consisting of: an epithelial sodium channel inhibitor, a lymphocyte function- associated antigen- 1 antagonist, an anti-inflammatory agent, a cholinergic agonist, a steroid, and an antibiotic.
  • the epithelial sodium channel inhibitor is amiloride; wherein the lymphocyte function-associated antigen-1 antagonist is lifitegrast; wherein the anti-inflammatory agent is cyclosporine; wherein the cholinergic agonist is pilocarpine or cevimeline; and wherein the steroid is a corticosteroid.
  • Embodiment 37 The method of any one of embodiments 1 to 36, wherein the patient is a human.
  • Embodiment 38 The method of any one of embodiments 1 to 37, wherein the patient has an open-circuit transepithelial potential difference, in response to contact with different solutions, that is lower than that of a control.
  • Embodiment 39 The method of any one of embodiments 1 to 38, further comprising testing the change in the open-circuit transepithelial potential difference, in response to contact with different solutions, at the surface of the eye of the patient, and comparing the result to a control.
  • Embodiment 40 A topical pharmaceutical composition comprising at least about 5 micrograms of at least one active agent and a pharmaceutically acceptable carrier; wherein the active agent is selected from a group consisting of:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl; or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is a C2-C4 haloalkyl
  • R 3 is hydrogen or a C1-C3 alkyl
  • R 4 is hydrogen or a C1-C3 alkyl
  • R 6 is:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 9 is:
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 6 is:
  • R 9 is:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 4 is hydrogen, methyl, or ethyl
  • Embodiment 41 The composition of embodiment 40 comprising from about 5 micrograms to about 1 gram of the active agent.
  • Embodiment 43 The composition of embodiment 40 comprising from about 5 micrograms to about 500 micrograms.
  • Embodiment 44 The composition of embodiment 40 comprising from about 5 micrograms to about 35 micrograms of the active agent.
  • Embodiment 45 The composition of embodiment 40 comprising about 10 micrograms.
  • Embodiment 46 A topical pharmaceutical composition comprising from about 1 nanomole to about 25 nmoles per 0.5 mL of an active agent and a pharmaceutically acceptable excipient; wherein the active agent is selected from a group consisting of:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl; or
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is a C2-C4 haloalkyl
  • R 3 is hydrogen or a C1-C3 alkyl
  • R 4 is hydrogen or a C1-C3 alkyl
  • R 6 is:
  • R 1 and R 6 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 9 is:
  • R 1 and R 9 are joined to form, together with the atoms to which they are attached, a substituted or unsubstituted C 8 -Cio heterocycloalkyl or a substituted or unsubstituted C 8 -Cio heteroaryl;
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 6 is: (i) hydrogen; or
  • R 9 is:
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 3 is hydrogen, methyl, or ethyl
  • R 4 is hydrogen, methyl, or ethyl
  • R 2 is -CH(CF 3 ) 2 or -CH 2 CF 2 CF 2 H;
  • R 4 is hydrogen, methyl, or ethyl
  • Embodiment 47 The composition of embodiment 46 comprising from about 1 nanomole to about 15 nmoles per 0.5 mL of the active agent.
  • Embodiment 48 The composition of embodiment 46 comprising from about 2 nanomoles to about 10 nmoles per 0.5 mL of the active agent.
  • Embodiment 49 The composition of embodiment 46 comprising about 3 nanomoles per 0.5 mL of the active agent.
  • Embodiment 50 The composition of any one of embodiments 40 or 49, wherein the topical pharmaceutical composition is a liquid pharmaceutical composition.
  • Embodiment 51 The composition of embodiment 50, wherein the liquid pharmaceutical composition is a solution, a suspension, or an emulsion.
  • Embodiment 52 The composition of embodiment 50, wherein the liquid pharmaceutical composition is an aqueous solution.
  • Embodiment 53 The composition of embodiment 50, wherein the liquid pharmaceutical composition is a suspension; and wherein the compound is micronized.
  • Embodiment 54 The composition of any one of embodiments 40 to 53, wherein the composition further comprises a pharmaceutically acceptable excipient.
  • Embodiment 55 The composition of embodiment 54, wherein the pharmaceutically acceptable excipient is a stabilizer, a co-solvent, or a combination thereof.
  • Embodiment 56 The composition of any one of embodiments 40 to 55, wherein the active agent is the compound of Formula (I) or the pharmaceutically acceptable salt thereof.
  • Embodiment 57 The composition of any one of embodiments 40 to 55, wherein the active agent is the compound of Formula (II) or the pharmaceutically acceptable salt thereof.
  • Embodiment 58 The composition of any one of embodiments 40 to 55, wherein the active agent is the compound of Formula (III) or the pharmaceutically acceptable salt thereof.
  • Embodiment 59 The composition of any one of embodiments 40 to 55, wherein the pharmaceutical composition comprises the compound of Formula (IV) or the pharmaceutically acceptable salt thereof.
  • Embodiment 60 The composition of any one of embodiments 40 to 55, wherein the active agent is Compound A or the pharmaceutically acceptable salt thereof.
  • Embodiment 61 The composition of any one of embodiments 40 to 55, wherein the active agent is Compound B or the pharmaceutically acceptable salt thereof.
  • Embodiment 62 The composition of any one of embodiments 40 to 55, wherein the active agent is Compound C or the pharmaceutically acceptable salt thereof.
  • Embodiment 63 The composition of any one of embodiments 40 to 55, wherein the active agent is Compound D or the pharmaceutically acceptable salt thereof.
  • Embodiment 64 The composition of any one of embodiments 40 to 55, wherein the active agent is Compound E or the pharmaceutically acceptable salt thereof.
  • Embodiment 65 An eye dropper for delivering a drop of a topical pharmaceutical composition to the eye of a patient; wherein the eye dropper comprises the topical composition of any one of embodiments 40 to 64.
  • Embodiment 66 The eye dropper of embodiment 65 having a volume sufficient to house 1 to 25 drops of the composition.
  • Embodiment 67 The eye dropper of embodiment 65 having a volume sufficient to house 1 to 15 drops of the composition.
  • Embodiment 68 The eye dropper of embodiment 65 having a volume sufficient to house 1 to 10 drops of the composition.
  • Embodiment 69 A kit comprising the eye dropper of any one of embodiments 65 to 68 and instructions for use.
  • Embodiment 70 The kit of embodiment 69, comprising seven eye droppers, fourteen eye droppers, twenty-eight eye droppers, or fifty-six eye droppers.
  • Embodiment 71 A kit comprising an eye dropper, a container which comprises the topical pharmaceutical composition of any one of embodiments 40 to 64, and instructions for use.
  • Embodiment 72 The kit of embodiment 71, comprising one eye dropper and one container; wherein the container comprises one dose of the composition.
  • Embodiment 73 The kit of embodiment 71, comprising two eye droppers and one container; wherein the container comprises two doses of the composition.
  • Embodiment 74 The kit of embodiment 71, comprising two eye droppers and two containers; wherein each container comprises one dose of the composition.
  • Embodiment 75 The kit of embodiment 71, comprising seven eye droppers and seven containers; wherein each container comprises one dose of the composition.
  • Embodiment 76 The kit of embodiment 71, comprising fourteen eye droppers and seven containers; wherein each container comprises two doses of the composition.
  • Embodiment 77 The kit of embodiment 71, comprising fourteen eye droppers and fourteen containers; wherein each container comprises one dose of the composition.
  • Embodiment 78. A method of identifying a patient for treatment with a modulator of ocular surface membrane transport, the method comprising the steps of:
  • Embodiment 79 The method of embodiment 78, wherein the ocular surface membrane transport is an ion transporter or a biomolecule transporter.
  • Embodiment 80 The method of embodiment 79, wherein the ion transporter is a chloride transporter, a potassium transporter, or a bicarbonate transporter; and wherein the biomolecule transporter is a glucose transporter or a urea transporter.
  • the ion transporter is a chloride transporter, a potassium transporter, or a bicarbonate transporter
  • the biomolecule transporter is a glucose transporter or a urea transporter.
  • Embodiment 81 The method of embodiment 79, further comprising treating the patient with a therapeutically effective amount of the modulator of ocular surface membrane transport.
  • Embodiment 82 The method of embodiment 79, wherein the modulator of ocular surface membrane transport is a CFTR agonist, a calcium-activated chloride channel activator, or an epithelial sodium channel (ENaC) inhibitor.
  • the modulator of ocular surface membrane transport is a CFTR agonist, a calcium-activated chloride channel activator, or an epithelial sodium channel (ENaC) inhibitor.
  • Embodiment 83 The method of embodiment 79, wherein the modulator of ocular surface membrane transport is a pharmaceutical composition of claims 46.
  • Embodiment 84 A method of identifying a patient for treatment with a modulator of intracellular signaling, the method comprising the steps of:
  • Embodiment 85 The method of embodiment 84 , wherein the modulator of intracellular signaling is cAMP, cGMP, or calcium signaling; wherein the modulator directly or indirectly modulates intracellular signaling.
  • Embodiment 86 The method of embodiment 84, further comprising treating the patient by administering a therapeutically effective amount of the pharmaceutical composition of claim 39 or 45.
  • Embodiment 87 The method of any one of embodiments, 78 to 86, wherein the ocular surface is the cornea or the conjunctiva.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/US2018/048025 2017-08-24 2018-08-24 OCULAR PHARMACEUTICAL COMPOSITIONS Ceased WO2019040919A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201880069116.7A CN111629730A (zh) 2017-08-24 2018-08-24 眼部药物组合物
CA3073718A CA3073718A1 (en) 2017-08-24 2018-08-24 Ocular pharmaceutical compositions
KR1020207008360A KR20200044873A (ko) 2017-08-24 2018-08-24 안구 제약학적 조성물
JP2020511176A JP2020531511A (ja) 2017-08-24 2018-08-24 眼球用医薬組成物
US16/641,621 US11839616B2 (en) 2017-08-24 2018-08-24 Ocular pharmaceutical compositions
AU2018321926A AU2018321926B2 (en) 2017-08-24 2018-08-24 Ocular pharmaceutical compositions
RU2020111560A RU2818087C2 (ru) 2017-08-24 2018-08-24 Офтальмологические фармацевтические композиции
EP18849250.8A EP3672598A4 (en) 2017-08-24 2018-08-24 OCULAR PHARMACEUTICAL COMPOSITIONS
US18/497,962 US20240156828A1 (en) 2017-08-24 2023-10-30 Ocular pharmaceutical compositions
US19/296,874 US20250367207A1 (en) 2017-08-24 2025-08-11 Ocular pharmaceutical compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762549872P 2017-08-24 2017-08-24
US62/549,872 2017-08-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/641,621 A-371-Of-International US11839616B2 (en) 2017-08-24 2018-08-24 Ocular pharmaceutical compositions
US18/497,962 Division US20240156828A1 (en) 2017-08-24 2023-10-30 Ocular pharmaceutical compositions

Publications (1)

Publication Number Publication Date
WO2019040919A1 true WO2019040919A1 (en) 2019-02-28

Family

ID=65439930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/048025 Ceased WO2019040919A1 (en) 2017-08-24 2018-08-24 OCULAR PHARMACEUTICAL COMPOSITIONS

Country Status (8)

Country Link
US (3) US11839616B2 (enExample)
EP (1) EP3672598A4 (enExample)
JP (1) JP2020531511A (enExample)
KR (1) KR20200044873A (enExample)
CN (1) CN111629730A (enExample)
AU (1) AU2018321926B2 (enExample)
CA (1) CA3073718A1 (enExample)
WO (1) WO2019040919A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021113580A1 (en) * 2019-12-05 2021-06-10 Vanda Pharmaceuticals Inc. Ophthalmic pharmaceutical compositions
WO2022056265A1 (en) * 2020-09-10 2022-03-17 Vanda Pharmaceuticals Inc. Methods of treating pde iv-mediated diseases or conditions
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
US12065412B2 (en) 2015-12-24 2024-08-20 The Regents Of The University Of California CFTR regulators and methods of use thereof
WO2025179141A1 (en) * 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957413B2 (en) * 2019-08-06 2024-04-16 University of Pittsburgh—of the Commonwealth System of Higher Education Solitary wave-based trans-lid tonometer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160317493A1 (en) * 2013-08-08 2016-11-03 Galapagos Nv Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis
WO2017112951A1 (en) * 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof
WO2017112950A1 (en) * 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPS62126178A (ja) 1985-11-26 1987-06-08 Mitsubishi Petrochem Co Ltd 新規トリアジン誘導体及びこれを含む除草剤
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
AU5433594A (en) 1992-11-19 1994-06-08 Dainippon Pharmaceutical Co. Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
US6403598B1 (en) * 1998-01-30 2002-06-11 R-Tech Ueno, Ltd. Ophthalmic composition
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
IL137655A0 (en) 1998-03-31 2001-10-31 Warner Lambert Co Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
JP4794793B2 (ja) 1999-12-28 2011-10-19 ファーマコペイア， インコーポレイテッド Ｎ−ヘテロ環ＴＮＦ−α発現阻害剤
IL160984A0 (en) 2001-09-21 2004-08-31 Reddy Us Therapeutics Inc Triazine derivatives and pharmaceutical compositions containing the same
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
HK1080074A1 (zh) 2002-10-01 2006-04-21 Johnson & Johnson Pharmaceutical Research & Development, Inc. 作为酪氨酸蛋白激酶抑制剂的4，6-二氨基取代-2-[氧基或氨氧基]-[1，3，5]三嗪
JP2006528640A (ja) 2003-07-22 2006-12-21 ニューロジェン・コーポレーション 置換ピリジン−２−イルアミン類縁体
ES2631362T3 (es) 2004-01-30 2017-08-30 Vertex Pharmaceuticals Incorporated Moduladores de transportadores de casete de unión a ATP
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2007095812A1 (en) 2006-02-27 2007-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof
CA2657093A1 (en) 2006-07-07 2008-01-10 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
KR101352709B1 (ko) 2007-05-22 2014-01-16 아스테라스 세이야쿠 가부시키가이샤 1위 치환 테트라히드로이소퀴놀린 화합물
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
EP2231624A4 (en) 2007-12-21 2011-07-06 Progenics Pharm Inc TRIAZINE AND CORRESPONDING COMPOUNDS WITH ANTIVIRAL EFFECT, COMPOSITIONS AND METHOD THEREFOR
JP5618837B2 (ja) 2008-03-05 2014-11-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ インスリン分泌刺激剤としてのキノキサリノン誘導体、それらを得る方法および糖尿病を治療するためのそれらの使用
CN102227430A (zh) 2008-10-23 2011-10-26 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
FR2958645B1 (fr) 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
WO2012092471A2 (en) 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
KR20150095925A (ko) 2012-12-19 2015-08-21 노파르티스 아게 Cftr 억제제로서의 트리시클릭 화합물
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
JP6716687B2 (ja) 2015-09-11 2020-07-01 イオン−トフ テクノロジーズ ゲーエムベーハー 二次イオン質量分析計及び二次イオン質量分析方法
US10035962B2 (en) * 2015-12-21 2018-07-31 Exxonmobil Research And Engineering Company Trim dewaxing of distillate fuel
AU2016377782B2 (en) 2015-12-24 2021-07-29 The Regents Of The University Of California CFTR regulators and methods of use thereof
KR20180128390A (ko) 2015-12-24 2018-12-03 레스피버트 리미티드 인돌리논 화합물과 섬유성 질환의 치료에서 이의 용도
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160317493A1 (en) * 2013-08-08 2016-11-03 Galapagos Nv Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis
WO2017112951A1 (en) * 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof
WO2017112950A1 (en) * 2015-12-24 2017-06-29 The Regents Of The University Of California Cftr regulators and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FLORES ET AL.: "Small-molecule CFTR activators increase tear secretion and prevent experimental dry eye disease", THE FASEB JOURNAL, 30 May 2016 (2016-05-30), pages 1789 - 1797, XP055580661, Retrieved from the Internet <URL:https://www.fasebj.org/doi/pdf/10.1096/fj.201500180> [retrieved on 20181008] *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12065412B2 (en) 2015-12-24 2024-08-20 The Regents Of The University Of California CFTR regulators and methods of use thereof
US11839616B2 (en) 2017-08-24 2023-12-12 The Regents Of The University Of California Ocular pharmaceutical compositions
WO2021113580A1 (en) * 2019-12-05 2021-06-10 Vanda Pharmaceuticals Inc. Ophthalmic pharmaceutical compositions
CN115397392A (zh) * 2019-12-05 2022-11-25 Vanda制药公司 眼用药物组合物
JP2023505255A (ja) * 2019-12-05 2023-02-08 バンダ・ファーマシューティカルズ・インコーポレイテッド 眼科用医薬組成物
WO2022056265A1 (en) * 2020-09-10 2022-03-17 Vanda Pharmaceuticals Inc. Methods of treating pde iv-mediated diseases or conditions
WO2025179141A1 (en) * 2024-02-22 2025-08-28 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Also Published As

Publication number Publication date
US20240156828A1 (en) 2024-05-16
US20250367207A1 (en) 2025-12-04
US20210154201A1 (en) 2021-05-27
EP3672598A1 (en) 2020-07-01
AU2018321926A1 (en) 2020-03-12
EP3672598A4 (en) 2021-04-28
CA3073718A1 (en) 2019-02-28
US11839616B2 (en) 2023-12-12
RU2020111560A (ru) 2021-09-24
KR20200044873A (ko) 2020-04-29
RU2020111560A3 (enExample) 2021-10-29
CN111629730A (zh) 2020-09-04
JP2020531511A (ja) 2020-11-05
AU2018321926B2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US20250367207A1 (en) Ocular pharmaceutical compositions
ES2972099T3 (es) Formulación oftálmica
JP5377293B2 (ja) 眼疾患の治療及び予防方法
US11192869B2 (en) CFTR regulators and methods of use thereof
US20200181097A1 (en) Cftr regulators and methods of use thereof
ES2389566T3 (es) Agente preventivo o terapéutico para tratar un transtorno de la córnea y la conjuntiva
JP4933897B2 (ja) 眼内移行性促進水性点眼剤
WO2016208961A1 (ko) 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물
Felix et al. Pro-secretory activity and pharmacology in rabbits of an aminophenyl-1, 3, 5-triazine CFTR activator for dry eye disorders
RU2818087C2 (ru) Офтальмологические фармацевтические композиции
AU2017219878A1 (en) Methods for the use of 5&#39;-adenosine diphosphate ribose (ADPR)
EP2072047A1 (en) Therapeutic agent for opthalmic disease
KR20130108376A (ko) 신경 보호 작용을 갖는 약제 배합

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18849250

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3073718

Country of ref document: CA

Ref document number: 2020511176

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018321926

Country of ref document: AU

Date of ref document: 20180824

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20207008360

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018849250

Country of ref document: EP

Effective date: 20200324